var title_f28_43_29360="Atrophie blanche lipodermatosclerosis";
var content_f28_43_29360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrophie blanche lipodermatosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrophie blanche of the medial ankle in a patient with lipodermatosclerosis consists of several white macular areas measuring 3 to 4 mm in diameter (arrows). These changes are caused by avascular fibrotic scars.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29360=[""].join("\n");
var outline_f28_43_29360=null;
var title_f28_43_29361="Determining BMI A";
var content_f28_43_29361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63600%7EENDO%2F74762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63600%7EENDO%2F74762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determining body mass index from weight and height",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"7\" rowspan=\"1\">",
"        Good weights",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\" rowspan=\"1\">",
"        Overweight",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        BMI, kg/m2",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Height, inches*",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"14\" rowspan=\"1\">",
"        Weight, pounds*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        58\"",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        191",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        59\"",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        119",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        198",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60\"",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        133",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        204",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        61\"",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        137",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        211",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        62\"",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        109",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        218",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        63\"",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        141",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        225",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        64\"",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        116",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        232",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65\"",
"       </td>",
"       <td>",
"        114",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66\"",
"       </td>",
"       <td>",
"        118",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        161",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        173",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        247",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        67\"",
"       </td>",
"       <td>",
"        121",
"       </td>",
"       <td>",
"        127",
"       </td>",
"       <td>",
"        134",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        223",
"       </td>",
"       <td>",
"        255",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        68\"",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        131",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        158",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        262",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        69\"",
"       </td>",
"       <td>",
"        128",
"       </td>",
"       <td>",
"        135",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        196",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        270",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70\"",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        181",
"       </td>",
"       <td>",
"        188",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        209",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        278",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        71\"",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        165",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        193",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        215",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        286",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        72\"",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        154",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        199",
"       </td>",
"       <td>",
"        206",
"       </td>",
"       <td>",
"        213",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        294",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        73\"",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        182",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        219",
"       </td>",
"       <td>",
"        227",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        302",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        74\"",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        155",
"       </td>",
"       <td>",
"        163",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        233",
"       </td>",
"       <td>",
"        272",
"       </td>",
"       <td>",
"        311",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75\"",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        192",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        279",
"       </td>",
"       <td>",
"        319",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        76\"",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        180",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        197",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        213",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        230",
"       </td>",
"       <td>",
"        238",
"       </td>",
"       <td>",
"        246",
"       </td>",
"       <td>",
"        287",
"       </td>",
"       <td>",
"        328",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The health risk from any level of BMI is increased if the patient has gained more than 5 kg (11 pounds) since age 25, or if the waist circumference is above 100 cm (40 in) due to central fatness",
"    <div class=\"footnotes\">",
"     * Divide weight by 2.2 to convert pounds into kilograms; multiply height by 2.54 to convert inches into centimeters.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determining body mass index using kilograms and centimeters*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        BMI, kg/m2",
"       </td>",
"       <td class=\"subtitle1\">",
"        19",
"       </td>",
"       <td class=\"subtitle1\">",
"        20",
"       </td>",
"       <td class=\"subtitle1\">",
"        21",
"       </td>",
"       <td class=\"subtitle1\">",
"        22",
"       </td>",
"       <td class=\"subtitle1\">",
"        23",
"       </td>",
"       <td class=\"subtitle1\">",
"        24",
"       </td>",
"       <td class=\"subtitle1\">",
"        25",
"       </td>",
"       <td class=\"subtitle1\">",
"        26",
"       </td>",
"       <td class=\"subtitle1\">",
"        27",
"       </td>",
"       <td class=\"subtitle1\">",
"        28",
"       </td>",
"       <td class=\"subtitle1\">",
"        29",
"       </td>",
"       <td class=\"subtitle1\">",
"        30",
"       </td>",
"       <td class=\"subtitle1\">",
"        35",
"       </td>",
"       <td class=\"subtitle1\">",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Height, cm*",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"14\" rowspan=\"1\">",
"        Weight, kg*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        147",
"       </td>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        86",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        150",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        152",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        155",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        96",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        158",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        160",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        102",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        162",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        105",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        165",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        109",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        168",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        113",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        170",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        116",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        173",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        120",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        175",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        107",
"       </td>",
"       <td>",
"        123",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        178",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        127",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        180",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        134",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        183&nbsp;",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        117",
"       </td>",
"       <td>",
"        134",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        185&nbsp;",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        103",
"       </td>",
"       <td>",
"        120",
"       </td>",
"       <td>",
"        137",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        188",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        102",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        141",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        190",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        144",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        193",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        101",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        108",
"       </td>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        149",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The health risk from any level of BMI is increased if the patient has gained more than 5 kg (11 pounds) since age 25, or if the waist circumference is above 100 cm (40 in) due to central fatness.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29361=[""].join("\n");
var outline_f28_43_29361=null;
var title_f28_43_29362="Toxicodendron range US";
var content_f28_43_29362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    US range of Toxicodendron species other than T. radicans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29362=[""].join("\n");
var outline_f28_43_29362=null;
var title_f28_43_29363="Thyrotropin alfa (recombinant human thyrotropin): Patient drug information";
var content_f28_43_29363=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Thyrotropin alfa (recombinant human thyrotropin): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/18/19749?source=see_link\">",
"     see \"Thyrotropin alfa (recombinant human thyrotropin): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F227397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F227398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Thyrogen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat thyroid cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to check thyroglobulin levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to thyrotropin alfa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3973742",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       At times the cancer tumor can get bigger for a few days after you are given this drug. It may affect your throat, voice, or breathing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12061 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29363=[""].join("\n");
var outline_f28_43_29363=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227397\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227398\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015898\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015897\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015902\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015903\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015905\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015900\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015907\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/18/19749?source=related_link\">",
"      Thyrotropin alfa (recombinant human thyrotropin): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_43_29364="Adenovirus inclusions liver";
var content_f28_43_29364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenoviral inclusions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of adenovirus type 5 hepatitis in a bone marrow transplant recipient who died from fulminant liver failure. Intranuclear viral inclusions are present within multiple hepatocytes, representing cells at different stages of infection with adenovirus (arrows). A \"smudge\" cell with a large inclusion that obscures the nucleus is present (center arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Phyllis Flomenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29364=[""].join("\n");
var outline_f28_43_29364=null;
var title_f28_43_29365="Perforating dermatosis 3";
var content_f28_43_29365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acquired reactive perforating dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29365=[""].join("\n");
var outline_f28_43_29365=null;
var title_f28_43_29366="Pralatrexate: Drug information";
var content_f28_43_29366=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pralatrexate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/35/43572?source=see_link\">",
"    see \"Pralatrexate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9407902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Folotyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9410906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Antifolate)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9410995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Initiate vitamin supplements before initial pralatrexate dose: Folic acid 1-1.25 mg/day orally beginning 10 days prior to initial pralatrexate dose; continue during treatment and for 30 days after last pralatrexate dose; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     1000 mcg I.M. within 10 weeks prior to initial pralatrexate dose and every 8-10 weeks thereafter (after initial dose, B",
"     <sub>",
"      12",
"     </sub>",
"     may be administered on the same day as pralatrexate).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prior to administering any dose, mucositis should be &le;grade 1 and absolute neutrophil count (ANC) should be &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; platelets should be &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     for the first dose and &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     for subsequent doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Peripheral T-cell lymphoma (PTCL), relapsed or refractory:",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 6 weeks of a 7-week treatment cycle; continue until disease progression or unacceptable toxicity (O&rsquo;Connor, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cutaneous T-cell lymphoma, relapsed or refractory (unlabeled use):",
"     </b>",
"     I.V.: 15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly for 3 weeks of a 4-week treatment cycle (Horwitz, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9410951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9410954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Moderate-to-severe renal impairment: Exposure and toxicities may be increased; monitor for toxicities and adjust dose accordingly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     End-stage renal disease (ESRD), including dialysis-dependent: Avoid use (unless the potential benefit outweighs risks).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9410955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patients with total bilirubin &gt;1.5 mg/dL, AST or ALT &gt;2.5 times the upper limit of normal (ULN), or ALT or AST &gt;5 times ULN if documented hepatic lymphoma involvement were excluded from clinical trials. Persistent abnormalities may indicate hepatotoxicity requiring dosage modification:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Grade 3 (AST or ALT &gt;5-20 times ULN or bilirubin &gt;3-10 times ULN): Omit dose; decrease to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     when recovers to &le;grade 2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Grade 4 (AST or ALT &gt;20 times ULN or bilirubin &gt;10 times ULN): Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F9410952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     Severe or intolerable adverse events may require dose omission, reduction or interruption. Do not make up omitted doses at the end of a cycle; do not re-escalate dose after a reduction due to toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Platelets:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (for 1-week duration): Omit dose; continue at previous dose if platelets recover within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (for 2-week duration): Omit dose; decrease to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     if platelets recover within 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     (for 3-week duration): Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      ANC:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     500-1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     without fever (for 1-week duration): Omit dose; continue at previous dose if ANC recovers within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     500-1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with fever",
"     <b>",
"      or",
"     </b>",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     (for 1-week duration): Omit dose, give filgrastim or sargramostim support; continue at previous dose (with growth factor support) if ANC recovers within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     500-1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with fever",
"     <b>",
"      or",
"     </b>",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     (recurrent or for 2-week duration): Omit dose and give filgrastim or sargramostim support; decrease to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (with growth factor support) if ANC recovers within 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     500-1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     with fever",
"     <b>",
"      or",
"     </b>",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     (second recurrence or for 3 week duration): Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Nonhematologic toxicity: Mucositis (on day of treatment):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 2: Omit dose; continue at previous dose when recovers to &le;grade 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 3 or recurrent grade 2: Omit dose and decrease to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     when recovers to &le;grade 1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 4: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Nonhematologic toxicity (other than mucositis):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 3: Omit dose; decrease to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     when recovers to &le;grade 2",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Grade 4: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9411001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folotyn&reg;: 20 mg/mL (1 mL, 2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9410904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9410996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. push (undiluted) over 3-5 minutes into the line of a free-flowing normal saline I.V.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F9410944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Normal saline",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9410907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F11433885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsed or refractory cutaneous T-cell lymphomas (mycosis fungoides [MF] and S&eacute;zary syndrome [SS])",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9407900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PRALAtrexate may be confused with methotrexate, PEMEtrexed, raltitrexed",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Folotyn&reg; may be confused with Focalin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9410917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Edema (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (36%), fever (32%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (15%; grades 3/4: 0%), pruritus (14%; grade 3: 2%; grade 4: 0%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Mucositis (70%; grade 3: 17%; grade 4: 4%), nausea (40%), constipation (33%), vomiting (25%), diarrhea (21%), anorexia (15%), abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (41%; grade 3: 14%; grade 4: 19%), anemia (34%; grade 3: 15%; grade 4: 2%), neutropenia (24%; grade 3: 13%; grade 4: 7%), leukopenia (11%; grade 3: 3%; grade 4: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Transaminases increased (13%; grade 3: 5%; grade 4: 0%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Limb pain (12%), back pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (28%), epistaxis (26%), dyspnea (19%), pharyngolaryngeal pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Night sweats (11%), infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Tachycardia (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Dehydration (serious &gt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenic fever (serious &gt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Sepsis (serious &gt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Bowel obstruction, cardiopulmonary arrest, lymphopenia, odynophagia, pancytopenia, skin exfoliation, skin ulceration, toxic epidermal necrolysis (TEN), tumor lysis syndrome (TLS)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9410913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9410914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bone marrow suppression: May cause thrombocytopenia, neutropenia and anemia; may require dosage modification. Monitor blood counts. Prophylactic folic acid and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     supplements are necessary to reduce hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic reactions: Severe and potentially fatal dermatologic reactions, including skin exfoliation, ulceration, and toxic epidermal necrolysis (TEN), have been reported. Skin reaction may be progressive; severity may increase with continued treatment; may also involve skin and subcutaneous tissues which are affected by lymphoma. Monitor all dermatologic reactions closely; withhold or discontinue treatment for severe dermatologic reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Hepatotoxicity and liver function test abnormalities have been observed with use. Monitor liver function. Persistent abnormalities may indicate hepatotoxicity and may require dosage modification.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Mucositis: Pralatrexate may cause mucositis (includes stomatitis or mucosal inflammation of gastrointestinal and genitourinary tracts). Monitor weekly; may require dosage modification. Prophylactic folic acid and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     supplements are necessary to reduce treatment-related mucositis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Tumor lysis syndrome (TLS): Pralatrexate may cause (TLS). Monitor closely; if TLS develops, treat for associated complications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Patients with moderate-to-severe renal impairment are at risk for increased exposure and toxicity. Avoid use in patients with end-stage renal disease (ESRD), including patients undergoing dialysis (unless the potential benefit outweighs potential risks); serious adverse reactions, including toxic epidermal necrolysis and mucositis were reported in patients with ESRD undergoing dialysis. Monitor renal function and  for systemic toxicity due to increased exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drugs with substantial renal clearance: Concurrent use with drugs with substantial renal clearance (eg, NSAIDs, sulfamethoxazole/trimethoprim) may result in delayed pralatrexate clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of BCRP",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9419305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of PRALAtrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sapropterin: PRALAtrexate may decrease the serum concentration of Sapropterin. Specifically, pralatrexate may decrease tissue concentrations of tetrahydrobiopterin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfamethoxazole: May increase the serum concentration of PRALAtrexate. More specifically, sulfamethoxazole may decrease excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of sulfamethoxazole. Monitor for decreased pralatrexate levels with discontinuation of sulfamethoxazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate. Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9410908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9410909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. May cause fetal harm if administered to a pregnant woman.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9410911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9410912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue breast-feeding or to discontinue pralatrexate should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Folotyn Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1 mL): $4134.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/2 mL (2 mL): $8268.74",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9410999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and weekly), serum chemistries, including renal and liver function tests (prior to the first and fourth doses in each cycle); mucositis severity (baseline and weekly); monitor for signs of tumor lysis syndrome",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9410993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antifolate analog; inhibits DNA, RNA, and protein synthesis by selectively entering cells expressing reduced folate carrier (RFC-1), is polyglutamylated by folylpolyglutamate synthetase (FPGS) and then competes for the DHFR-folate binding site to inhibit dihydrofolate reductase (DHFR)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9410945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution:",
"     <i>",
"      S",
"     </i>",
"     -diastereomer: 105 L;",
"     <i>",
"      R",
"     </i>",
"     -diastereomer: 37 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~67%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 12-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~34% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Foss FM, Horwitz SM, Pinter-Brown L, et al, &ldquo;Pralatrexate is an Effective Treatment for Heavily Pretreated Patients With Relapsed/Refractory Transformed Mycosis Fungoides (tMF),&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):1762 [abstract 1762 from ASH 2010 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goy A, Pro B, Savage KJ, et al, &ldquo;Pralatrexate is Effective in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) With Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):1753 [abstract 1753 from ASH 2010 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horwitz SM, Kim YH, Foss F, et al, &ldquo;Identification of an Active, Well-Tolerated Dose of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 119(18):4115-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/43/29366/abstract-text/22394596/pubmed\" id=\"22394596\" target=\"_blank\">",
"        22394596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horwitz SM, Kim YH, Foss FM, et al, &ldquo;Identification of an Active, Well-Tolerated Dose of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2010, 116(21):2800 [abstract 2800 from ASH 2010 Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Izbicka E, Diaz A, Streeper R, et al, &ldquo;Distinct Mechanistic Activity Profile of Pralatrexate in Comparison to Other Antifolates in",
"      <i>",
"       in vitro",
"      </i>",
"      and",
"      <i>",
"       in vivo",
"      </i>",
"      Models of Human Cancers,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2009, 64(5): 993-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/43/29366/abstract-text/19221750/pubmed\" id=\"19221750\" target=\"_blank\">",
"        19221750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Non-Hodgkin&rsquo;s Lymphomas,&rdquo; Version 1.2011. Available at file://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Connor OA, Horwitz S, Hamlin P, et al, &ldquo;Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(26):4357-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/43/29366/abstract-text/19652067/pubmed\" id=\"19652067\" target=\"_blank\">",
"        19652067",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor OA, Pro B, Pinter-Brown L, et al, &ldquo;Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the Pivotal PROPEL Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(9):1182-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/43/29366/abstract-text/21245435/pubmed\" id=\"21245435\" target=\"_blank\">",
"        21245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor O, Pro B, Pinter-Brown L, et al, &ldquo;PROPEL: Results of the Pivotal, Multicenter, Phase II Study of Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(15S):8561 [abstract 8561 from 2009 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9530 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29366=[""].join("\n");
var outline_f28_43_29366=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9407902\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410906\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410995\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410951\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410954\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410955\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410952\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9411001\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410904\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410996\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410944\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410907\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11433885\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9407900\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410917\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410913\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410914\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299929\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9419305\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410908\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410909\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410911\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410912\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322721\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410999\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410993\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9410945\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9530|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/35/43572?source=related_link\">",
"      Pralatrexate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_43_29367="Peripartum hysterectomy";
var content_f28_43_29367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peripartum hysterectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29367/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29367/contributors\">",
"     Allan J Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29367/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29367/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29367/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/43/29367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripartum hysterectomy may be performed as an emergency to save the life of a woman with persistent bleeding, or as planned procedure, often in conjunction with cesarean delivery (",
"    <a class=\"graphic graphic_table graphicRef66005 \" href=\"UTD.htm?16/21/16731\">",
"     table 1",
"    </a>",
"    ). In the United States, it is performed in 0.08 percent of all deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/1\">",
"     1",
"    </a>",
"    ] and 0.5 percent of cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar results have been reported in Canada and in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common indication for emergency procedures is severe uterine hemorrhage that cannot be controlled by conservative measures. Such hemorrhage may be due to abnormal placentation (eg, placenta accreta), uterine atony, uterine rupture, leiomyomas, coagulopathy, or laceration of a uterine vessel not treatable by more conservative measures. The relative frequency of these conditions varies among series and is dependent upon the patient population and practice patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/4-11\">",
"     4-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Planned hysterectomy at the time of delivery is controversial because of increased morbidity related to surgery on the highly vascular pelvic organs. It has been advocated for parturients with gynecologic disorders such as leiomyomas or high-grade cervical intraepithelial neoplasia. However, in these cases, surgery usually can be safely delayed until the pelvis returns to its prepregnant state [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/12\">",
"     12",
"    </a>",
"    ]. Peripartum hysterectomy may also be scheduled for patients with stages IA2 and IB1 cervical carcinoma, which can be managed by radical hysterectomy following a planned cesarean delivery.",
"   </p>",
"   <p>",
"    Hysterectomy (surgical removal of the uterus) also may be appropriate for women with postpartum uterine infection unresponsive to antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DECISION MAKING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sequence of conservative measures to control uterine hemorrhage should be attempted before resorting to more radical surgical procedures (",
"    <a class=\"graphic graphic_table graphicRef57307 \" href=\"UTD.htm?22/39/23166\">",
"     table 2",
"    </a>",
"    ). If an intervention does not succeed, the next treatment in the sequence should be swiftly instituted. Indecisiveness delays therapy and results in possibly fatal excessive hemorrhage. Moreover, there is increased blood loss with increased duration of time before performance of hysterectomy. This, in turn, increases the likelihood that the hysterectomy will be seriously complicated by coagulopathy, severe hypovolemia, tissue hypoxia, hypothermia, and acidosis, which further compromise the patient's status. Timing is critical to an optimal outcome: hysterectomy should not be performed too early or too late.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many instances, the obstetrician can anticipate the possible need for postpartum hysterectomy and the woman can be apprised of this risk in the antenatal period. When obtaining informed consent prior to labor and delivery, the indications for peripartum hysterectomy, the chances of needing the procedure, and the possible outcome should be discussed with the patient and documented. This is particularly important in patients who have an underlying condition (eg, placenta previa, significant leiomyomas) and are at increased risk of needing peripartum hysterectomy.",
"   </p>",
"   <p>",
"    Women with a placenta previa following previous cesarean delivery are at especially high risk of abnormal placental attachment requiring hysterectomy to control hemorrhage. In a population based, case-control study, the risk of needing a peripartum hysterectomy was lowest in women undergoing a first delivery that was vaginal (1 in 30,000) and highest in women with a history of two or more prior cesarean deliveries (1 in 220) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/13\">",
"     13",
"    </a>",
"    ]. A study of 30,000 women undergoing cesarean delivery reported the risk of peripartum hysterectomy was &lt;1 percent with the first, second, or third cesareans, 2 to 4 with the fourth and fifth procedures, and 9 percent after six or more cesareans [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=see_link&amp;anchor=H3937600#H3937600\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atony is a common cause of postpartum hemorrhage and may be related to prolonged labor, chorioamnionitis, use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    , multiple gestation, or delivery of a large infant.",
"   </p>",
"   <p>",
"    Uterine rupture, although uncommon, can cause massive intraabdominal hemorrhage associated with a small volume of vaginal hemorrhage. It occurs primarily in women with prior hysterotomy scars (eg, cesarean delivery or myomectomy), but occasionally is seen in those receiving excessive uterine stimulation from uterotonic drugs.",
"   </p>",
"   <p>",
"    A systematic review including 981 cases of emergency postpartum hysterectomy reported the following indications and their frequencies: abnormal placental attachment (placenta accreta, increta and percreta) (38 percent), uterine atony (29 percent), uterine rupture (12 percent), undefined bleeding (9 percent), placenta previa (7 percent), abruptio placenta (2 percent), leiomyoma (1 percent), hematoma (&lt;1 percent) and other (1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The obstetrician should be prepared for the possibility of having to perform a peripartum hysterectomy, especially in high-risk situations or in the presence of heavy postpartum bleeding. We suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluating patients with placenta previa with ultrasound for possible placenta accreta",
"     </li>",
"     <li>",
"      Scheduling the delivery during regularly scheduled operative hours, if possible.",
"     </li>",
"     <li>",
"      Cross-matching four units of packed red blood cells for patients with large leiomyomas or prior classical cesarean delivery, myomectomy, or placenta previa without prior cesarean delivery. Patients with placenta previa following cesarean delivery or ultrasound findings compatible with placenta accreta, should have more blood products available (I suggest 10 to 20 units of packed red blood cells, 4 units of fresh frozen plasma, and 5 units of single donor platelets).",
"     </li>",
"     <li>",
"      Inserting a three-way Foley catheter in the bladder to drain urine and to facilitate instillation of fluid to test bladder integrity, if required intraoperatively. Ureteral stents can be placed preoperatively if the patient is at high risk of parametrial dissection and the surgeon feels they will be helpful.",
"     </li>",
"     <li>",
"      Placing intermittent compression stockings to reduce the risk of deep vein thrombophlebitis.",
"     </li>",
"     <li>",
"      Administering prophylactic antibiotics to decrease the risk of postoperative infection.",
"     </li>",
"     <li>",
"      Informing the anesthesiologist of the increased possibility of hysterectomy.",
"     </li>",
"     <li>",
"      Assembling an operating room staff with experience in the procedures that might be performed (eg, hysterectomy, uterine and iliac artery ligation, ureteral stenting or surgery). At least two surgical assistants should be available, one capable of taking an active part in the operation and one who can provide adequate traction and exposure.",
"      <br/>",
"      <br/>",
"      An obstetrician who infrequently performs major gynecologic surgery or who does not have experience performing the procedures potentially required should ask a more experienced gynecologist to participate in the procedure or be available to assist.",
"     </li>",
"     <li>",
"      Appropriate instrumentation should be available: (1) a self-retaining retractor designed to give adequate lateral exposure (eg, Balfour or Bookwalter); the O'Connor-O'Sullivan retractor often provides insufficient lateral exposure, (2) a sufficient number of pedicle clamps adequate to hold tissue without tearing or slippage (I have four curved clamps, such as Heaney, Rogers, or Zeppelin clamps, and two straight clamps, such as Ballantine or straight Zeppelin clamps available. I find Kocher and Phaneuf clamps inadequate to hold tissue securely), (3) Kelly, tonsil, and right angle clamps to aid with the dissection, (4) an electrodissection unit, and (5) two suction devices. A heavy absorbable suture, such as #1 chromic gut or polyglycolic acid, is used for suturing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OPERATIVE PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripartum hysterectomy differs from nongravid hysterectomy in several important respects, most of which make the operation more difficult.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the cervix has undergone significant dilation and effacement, it will be soft and may be difficult to identify. The obstetrician can tag the external os before the operation with two to four evenly spaced sutures of #0 or #1 polyglycolic acid or with metal clips in order to facilitate later identification of the exocervix (if the patient is sufficiently stable and is in stirrups).",
"     </li>",
"     <li>",
"      Blood vessels throughout the pelvis are greatly dilated, and varices are often found in the mesosalpinx, so massive hemorrhage may obscure the operative field.",
"     </li>",
"     <li>",
"      The uterus is larger than normal.",
"     </li>",
"     <li>",
"      Tissue may be friable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, surgical planes are usually easy to identify and develop.",
"   </p>",
"   <p>",
"    Supracervical hysterectomy is thought to be safer than total hysterectomy in this setting and is a reasonable option unless there is specific indication for removal of the cervix, such as cervical neoplasia, cervical bleeding, or placenta previa. However, a retrospective cohort study found no difference in complication rates between the two procedures when performed after emergency cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/16\">",
"     16",
"    </a>",
"    ]. Surgical expertise and patient specific factors should determine the choice of procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2976705591\">",
"    <span class=\"h2\">",
"     Exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placing the patient in Trendelenburg position, routine use of a self-retaining retractor, and packing the abdominal contents can facilitate visualization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate exposure facilitates a rapid and safe operation. A vertical skin incision is optimal; a transverse skin incision should be as wide as possible and the surgeon should be prepared to divide the rectus muscles if exposure from a Pfannenstiel incision does not provide adequate exposure. Delivery at a planned cesarean hysterectomy is best accomplished through a classical or low vertical uterine incision, which can rapidly be made hemostatic using towel clips or a single running layer with sturdy suture (eg, loop #1 PDS) on a large needle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The technique should be simple enough to perform rapidly and should minimize the creation of dead space and raw surfaces because of the possibility of coexistent coagulopathy. The procedure is begun by using electrodissection to lyse adhesions to the uterus. When the uterus is free, the fundus is extracorporealized and an assistant maintains traction on the fundus until the uterus is removed.",
"   </p>",
"   <p>",
"    If cesarean delivery was performed, the bladder flap will have been developed. Otherwise, a transverse incision of the anterior uterine peritoneum is made using electrodissection 1 cm distal to the bladder reflection and extending from one round ligament to the other. The vesicocervical space is developed and bladder pillars divided, but no further distally than will be necessary to allow exposure and clamping of the uterine vessels. This separation of the bladder is accomplished by gently spreading the tips of Metzenbaum scissors or a tonsil clamp in the areolar tissue and using electrodissection to coagulate small vessels. Gentle finger dissection may speed the procedure once good planes have been created, but blunt dissection with a sponge stick is inadvisable, as massive bleeding or bladder laceration may result. If scarring has obliterated the vesicocervical space (as can occur after previous cesarean deliveries), sharp dissection with Metzenbaum scissors may be necessary to perform this dissection.",
"   </p>",
"   <p>",
"    Each round ligament is doubly clamped near the uterus with curved clamps whose concave surface is directed medially. The tissue between the clamps is divided using Mayo scissors or a cutting current and each clamp is replaced with a suture ligature (",
"    <a class=\"graphic graphic_figure graphicRef75821 \" href=\"UTD.htm?18/17/18712\">",
"     figure 1",
"    </a>",
"    ). The tube, utero-ovarian ligament, and ovarian vessels are then clamped close to the uterus using two curved clamps. This should be done in a single bundle, if possible, but may require multiple pedicles on each side if the bundle is too large to ligate safely. The tissue between the clamps is divided and the pedicles sutured. In the presence of severe hemorrhage, however, the operation can be performed more rapidly if the pedicles are not sutured until all of the vascular structures to the uterine arteries have been clamped and divided. This requires a sufficient number of clamps to be available. Use of a bipolar ligature device, such as the LigaSure instrument, allows the procedure to be performed more rapidly but, in our experience, hemostasis is not as secure.",
"   </p>",
"   <p>",
"    The ureters are identified by visualizing them through the peritoneum of the posterior broad ligament. Their position should be confirmed frequently during the remainder of the procedure. If the ureter runs close to the cervix or cannot be identified, the surgeon should divide the posterior peritoneum of the broad ligament sharply (instead of by clamping as described below) in order to displace the ureter posteriorly.",
"   </p>",
"   <p>",
"    For the remainder of the procedure, it is important that the uterus be maintained on traction to pull it and the cervix away from the ureter. It is also important that adequate exposure be achieved using packs and a self-retaining retractor, such as a Balfour retractor.",
"   </p>",
"   <p>",
"    The broad ligament is clamped at its junction with the uterus, using the clamp-cut-ligate technique described above. This will require several bites. The heel of the outer clamp should rest just medial to the previous pedicle, leaving no unsutured gap to bleed, and the tip of the clamp should rest against the uterus with each bite. The final pedicle will contain the uterine vessels.",
"   </p>",
"   <p>",
"    A supracervical hysterectomy can be performed by amputating the fundus from the uterus using scissors. The proximal edge of the cervix is oversewn with figure-of-eight or running sutures. Bleeding is controlled using standard surgical techniques.",
"   </p>",
"   <p>",
"    Alternatively, if the cervix is to be removed, the cul-de-sac is examined to ensure that the rectal reflection is not abnormally high. The bladder is further reflected off the entire cervix and the proximal 3 cm of vagina to completely free the bladder. An incision is made in the midline of the lower uterine segment. Sutures used to tag the external cervical os can now be palpated through this incision and are used to define the distal limit of dissection. Each cardinal ligament is divided in several bites by clamping close to the cervix with a straight clamp, dividing the tissue medially with scissors or a scalpel, and suturing the pedicle. When dissection of the cardinal ligaments has reached the external os, the surgeon carefully inspects the field to ensure that the ureter and bladder are outside the dissection planes. The vaginal angle and uterosacral ligament on each side are clamped into a bundle with a curved clamp. The vagina is then severed with scissors medial to each clamp. Following this, each clamp is replaced with a suture ligature. The resulting pedicle is sutured to the medial cardinal ligament pedicle to provide support for the vaginal cuff. The remainder of the vaginal cuff is closed side to side with a running suture. The ovary can be stabilized by suturing the medial pedicle to the peritoneum of the pelvic sidewall using #00 polyglycolic acid suture on a gastrointestinal needle to stabilize the ovary and prevent torsion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Evaluation of bladder and ureteral integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrity of the bladder can be confirmed by infusing 200 mL of saline mixed with two or three drops of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    into the bladder through the Foley catheter; extravasation of blue fluid signifies a leak. The ureters are inspected to determine that they are intact and patent. This may be tested by injecting one to two ampules (5 mL per ampule) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/10/15522?source=see_link\">",
"     indigo carmine",
"    </a>",
"    intravenously; blue urine will spill into the pelvis in 10 to 15 minutes if a ureter has been cut. Cystoscopy or direct visualization of the ureters through a cystotomy should demonstrate urine passing through both ureteral orifices. Absence of this finding suggests that one or both ureters are obstructed as a result of surgery. A ureteral stent can be passed through the ureteral orifice to localize the site of obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The abdomen is closed using any standard technique after ensuring good hemostasis. No drains are necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Key points",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the procedure is delayed until there is a significant coagulopathy, hemostasis may not be possible, and pelvic packing may be necessary (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Pelvic packing'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Inadequate exposure or traction may lead to vascular or ureteral injury.",
"     </li>",
"     <li>",
"      It may be difficult to determine the boundary between the cervix and vagina, as a dilated cervix is effaced and soft. Placing sutures or clips to \"tag\" the cervix reduces this problem.",
"     </li>",
"     <li>",
"      If the bladder does not reflect readily off the cervix, it should be opened at the dome. Palpation and inspection of the posterior bladder from the interior makes it easier to find the dissection plane between these two organs. In addition, the cervix may be fused to the bladder (especially if there is placental percreta), thus requiring resection of a portion of the bladder. Consultation with a gynecologic oncologist or urologist is warranted if the surgeon is not familiar with bladder surgery.",
"     </li>",
"     <li>",
"      Every attempt should be made to identify the ureter and avoid ligating it. However, control of hemostasis is more important than preserving the ureter intact. Ligation of one or both ureters can be reversed during a repeat operation after hemostasis has been achieved and coagulopathy and hypovolemia have been corrected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTROL OF PERSISTENT PELVIC BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding in the deep pelvis may persist following hysterectomy. Hemostasis may be achieved by placing running and figure-of-eight sutures of heavy absorbable suture material in bleeding areas. If this does not control bleeding, then a variety of additional procedures can be tried:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hemostatic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemostatic substances can be applied topically to control intraoperative bleeding when suture ligation and cautery have failed. Collagen derivatives (eg, Gelfoam, Avitene, Surgicel) with or without thrombin impregnation are one type of hemostatic product; biological and synthetic sealants (eg, FloSeal Matrix) are newer forms of these agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gelfoam is a pliable product prepared from purified pork skin gelatin granules. Gelfoam powder is made into a paste and smeared onto the bleeding site, while Gelfoam sponges are cut to the appropriate size and applied to the site; both are held to the bleeding area with moderate pressure. Gelfoam functions, in part, by being able to absorb many times its weight of blood; it does not appear to affect the mechanism for blood clotting. The material is gradually absorbed over a period of weeks.",
"     </li>",
"     <li>",
"      Fibrin sealant, or fibrin \"glue,\" is a unique surgical",
"      <span class=\"nowrap\">",
"       hemostatic/adhesive",
"      </span>",
"      material that is being utilized with increasing frequency in a variety of surgical situations. It is a two-component system in which a solution of concentrated fibrinogen and factor XIII are combined with a solution of thrombin and calcium in order to form a coagulum, simulating the final stage of the clotting cascade. Once the",
"      <span class=\"nowrap\">",
"       thrombin/calcium",
"      </span>",
"      is combined with the",
"      <span class=\"nowrap\">",
"       fibrinogen/factor",
"      </span>",
"      XIII, a fibrin clot forms in seconds, or somewhat slower if a more dilute form of thrombin is used. In some preparations, or in selected indications, an antifibrinolytic agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/52/6982?source=see_link\">",
"       aprotinin",
"      </a>",
"      ) is included, presumably to prevent lysis of the clot. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=see_link\">",
"       \"Fibrin sealant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"       Topical thrombin",
"      </a>",
"      powder can be applied directly as a powder or as reconstituted solution of 1000",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      sprayed onto a gelatin sponge and placed at the site of bleeding.",
"     </li>",
"     <li>",
"      Gelatin matrix thrombin solution (FloSeal) is a combination of specially engineered gelatin granules and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40612?source=see_link\">",
"       topical thrombin",
"      </a>",
"      . It is a high viscosity gel clinically proven to control bleeding from capillary oozing to arterial spurting. It is applied against the bleeding surface and then compressed with gauze sponge. Hemostasis is typically achieved within two minutes, at which time the gauze sponge is removed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When Gelfoam with thrombin and FloSeal Matrix were compared in two randomized trials (nongynecological surgery), both were safe and easy to use, but FloSeal Matrix provided more rapid and effective hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These agents should not be used for intravascular injection, in closure of skin incisions, or for treatment of bleeding from the endometrium. They also should not be used in infected tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding from veins in the presacral space is difficult to control and can easily lead to exsanguination. These veins are intimately associated with the sacral periosteum, thus are difficult to suture or clip. This bleeding sometimes can be controlled by pressing sterile thumbtacks into the anterior sacrum so that the tack head is pressed against the bleeding point [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pelvic packing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Packing is a last resort that usually succeeds in controlling low pressure (microvascular or venous) bleeding confined to the pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/21\">",
"     21",
"    </a>",
"    ]. We tie several Kerlix bandages together end to end to form one long strip for packing. The dry bandages are packed firmly, but carefully, into the pelvis so that the pack fills all interstices but does not abrade pelvic tissue. If the packing is successful, no blood will be seen seeping through or around the gauze after 10 minutes observation.",
"   </p>",
"   <p>",
"    The free end of the gauze is brought through the inferior end of a vertical skin incision or the center of a horizontal skin incision. The incision is then closed in a routine manner, with the free end protruding against a composite dressing with ample gauze. Broad spectrum antibiotics are given until the packing is removed, usually 48 hours after insertion.",
"   </p>",
"   <p>",
"    Different surgeons practice slight variations of this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/22-30\">",
"     22-30",
"    </a>",
"    ]. One variation is to fill a sterile plastic bag (eg, drawstring bag used to cover x-ray film) or cloth container with gauze and place it against the pelvic bleeders. The drawstrings are pulled through the vagina and attached to a weight, which provides traction so that the pack exerts pressure against the pelvic floor. An alternative method of pelvic packing is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending on the technique used, laparotomy may be needed to remove the pack or it may be removed through the vagina or another conduit. Postoperative fever is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pack removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gauze pack is removed under general anesthesia on the second day after insertion. Bleeding may resume if the pack is removed too early or in the presence of coagulopathy, whereas pelvic infection is likely if removal is delayed.",
"   </p>",
"   <p>",
"    The surgeon opens the incision and gently removes the gauze tape. Adhesions and purulent discharge often are encountered when the pack is removed. Irrigation with warm saline may be necessary to separate the gauze from the pelvic structures.",
"   </p>",
"   <p>",
"    After removing the gauze, the pelvis is observed for pooling of blood. The surgeon should resist the temptation to retract pelvic structures to inspect the operative bed and should not insert sponges or suction tips, which may reactivate bleeding. If no bleeding is observed, the pelvis is irrigated copiously with warm saline until the solution is clear. A covered Poole suction device is used to aspirate the irrigating solution in order to avoid suctioning against raw tissue, which could reactivate bleeding. If there is significant bleeding, the pelvis should be inspected and bleeding sites controlled using standard techniques. A new pack may be inserted if bleeding cannot be controlled by other measures. The abdomen is closed in the usual manner. In one series, packing successfully controlled obstetric hemorrhage in seven of eight cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal complications after peripartum hysterectomy are hemorrhage, urinary tract injury, coagulopathy, and infection. Emergency procedures are associated with a higher rate of complications than planned procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/32\">",
"     32",
"    </a>",
"    ]. Mortality should be less than 1 percent, even in emergency cases. The range of findings from several large series is illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective series by the Maternal-Fetal Medicine Units Network included 186 cesarean hysterectomies performed in 1999 and 2000, and reported the following complications and their frequencies: red blood cell transfusion (84 percent), transfusion of other blood products (34 percent), fever (11 percent), ileus (5 percent), exploratory laparotomy (4 percent), hospital readmission (4 percent), urinary tract infection (3 percent), cuff abscess (2.7 percent), maternal death (1.6 percent), bowel injury (1 percent), wound dehiscence (1 percent), pelvic or deep vein thrombosis (1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from the Nationwide Inpatient Sample (a random sample of 20 percent of hospital discharges in the United States) from 1998 to 2007 showed the following types and rates of complications in 4967 peripartum hysterectomies: transfusion (46 percent), infection (12 percent), wound complication (10 percent), bladder injury (9 percent), reoperation (4 percent), venous thromboembolism (1 percent); and intestinal, ureteral, or vascular injury (&le;1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/33\">",
"       33",
"      </a>",
"      ]. Transfusion, infection, urinary tract injury, and reoperation were far more frequent than in nonobstetric hysterectomy.",
"     </li>",
"     <li>",
"      A review of six studies of peripartum hysterectomy reported the following ranges of complications: febrile morbidity (11 to 34 percent), cystotomy (6 to 29 percent), ureteral injury (2 to 7 percent), oophorectomy (6 percent), reoperation (4 to 33 percent), thromboembolism (1 to 4 percent), death (0 to 4.2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29367/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The woman receives routine posthysterectomy and postpartum care, provided she is stable. If the operation was clean-contaminated, no postoperative antibiotics are indicated, but a contaminated case may require treatment with broad spectrum antibiotics such as a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . The Foley catheter is continued until urinary output is stable and ambulation to a commode or bathroom is possible. The woman is restricted to clear liquids on the day after surgery, but advanced to a regular diet on the second day, if there are no problems. Patient controlled analgesia is preferable until she can take oral medicine. Wound care is conducted according to the surgeon's preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripartum hysterectomy may be performed either as an emergency to save the life of a woman with persistent bleeding, or as planned procedure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a relationship between the duration of time that passes prior to deciding to perform an emergency hysterectomy, the amount of blood loss, and the likelihood that the hysterectomy will be seriously complicated by coagulopathy, severe hypovolemia, tissue hypoxia, hypothermia, and acidosis, which further compromise the patient's status. Timing is critical to an optimal outcome: hysterectomy should not be performed too early or too late. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Decision making'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripartum hysterectomy differs from nongravid hysterectomy in several important respects, most of which make the operation more difficult. Supracervical hysterectomy may be safer than total hysterectomy and is a reasonable option unless there is specific indication for removal of the cervix. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Operative procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A Pfannenstiel incision may not provide sufficient exposure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Incision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Placing sutures or clips to \"tag\" the cervix reduces the difficulty in determining the boundary between the cervix and vagina. If the bladder does not reflect readily off the cervix, it should be opened at the dome to aid in the dissection. Reasonable attempts should be made to identify the ureter. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Key points'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methods for controlling persistent pelvic bleeding include suture ligation, use of hemostatic agents, tacks, and pelvic packing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Control of persistent pelvic bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal complications of peripartum hysterectomy are hemorrhage, urinary tract injury, coagulopathy, and infection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/1\">",
"      Bateman BT, Mhyre JM, Callaghan WM, Kuklina EV. Peripartum hysterectomy in the United States: nationwide 14 year experience. Am J Obstet Gynecol 2012; 206:63.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/2\">",
"      Shellhaas CS, Gilbert S, Landon MB, et al. The frequency and complication rates of hysterectomy accompanying cesarean delivery. Obstet Gynecol 2009; 114:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/3\">",
"      Zwart JJ, Dijk PD, van Roosmalen J. Peripartum hysterectomy and arterial embolization for major obstetric hemorrhage: a 2-year nationwide cohort study in the Netherlands. Am J Obstet Gynecol 2010; 202:150.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/4\">",
"      Clark SL, Yeh SY, Phelan JP, et al. Emergency hysterectomy for obstetric hemorrhage. Obstet Gynecol 1984; 64:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/5\">",
"      Chestnut DH, Eden RD, Gall SA, Parker RT. Peripartum hysterectomy: a review of cesarean and postpartum hysterectomy. Obstet Gynecol 1985; 65:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/6\">",
"      Sturdee DW, Rushton DI. Caesarean and post-partum hysterectomy 1968-1983. Br J Obstet Gynaecol 1986; 93:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/7\">",
"      Al-Sibai MH, Rahman J, Rahman MS, Butalack F. Emergency hysterectomy in obstetrics--a review of 117 cases. Aust N Z J Obstet Gynaecol 1987; 27:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/8\">",
"      Lau WC, Fung HY, Rogers MS. Ten years experience of caesarean and postpartum hysterectomy in a teaching hospital in Hong Kong. Eur J Obstet Gynecol Reprod Biol 1997; 74:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/9\">",
"      Zorlu CG, Turan C, I��ik AZ, et al. Emergency hysterectomy in modern obstetric practice. Changing clinical perspective in time. Acta Obstet Gynecol Scand 1998; 77:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/10\">",
"      Glaze S, Ekwalanga P, Roberts G, et al. Peripartum hysterectomy: 1999 to 2006. Obstet Gynecol 2008; 111:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/11\">",
"      Bodelon C, Bernabe-Ortiz A, Schiff MA, Reed SD. Factors associated with peripartum hysterectomy. Obstet Gynecol 2009; 114:115.",
"     </a>",
"    </li>",
"    <li>",
"     Plauch&eacute;, WC. Obstetric hysterectomy. In: Operative Obstetrics, Hankins, GDV, Clark, SL, Cunningham, FG, Gilstrap, LC III (Eds), Appleton &amp; Lange, Norwalk, Connecticut 1995. p.333.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/13\">",
"      Knight M, Kurinczuk JJ, Spark P, et al. Cesarean delivery and peripartum hysterectomy. Obstet Gynecol 2008; 111:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/14\">",
"      Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/15\">",
"      Rossi AC, Lee RH, Chmait RH. Emergency postpartum hysterectomy for uncontrolled postpartum bleeding: a systematic review. Obstet Gynecol 2010; 115:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/16\">",
"      Imudia AN, Hobson DT, Awonuga AO, et al. Determinants and complications of emergent cesarean hysterectomy: supracervical vs total hysterectomy. Am J Obstet Gynecol 2010; 203:221.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/17\">",
"      Wright JD, Bonanno C, Shah M, et al. Peripartum hysterectomy. Obstet Gynecol 2010; 116:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/18\">",
"      Weaver FA, Hood DB, Zatina M, et al. Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery. Ann Vasc Surg 2002; 16:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/19\">",
"      Oz MC, Cosgrove DM 3rd, Badduke BR, et al. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. Ann Thorac Surg 2000; 69:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/20\">",
"      Nivatvongs S, Fang DT. The use of thumbtacks to stop massive presacral hemorrhage. Dis Colon Rectum 1986; 29:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/21\">",
"      Finan MA, Fiorica JV, Hoffman MS, et al. Massive pelvic hemorrhage during gynecologic cancer surgery: \"pack and go back\". Gynecol Oncol 1996; 62:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/22\">",
"      Dildy GA, Scott JR, Saffer CS, Belfort MA. An effective pressure pack for severe pelvic hemorrhage. Obstet Gynecol 2006; 108:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/23\">",
"      Ghourab S, Al-Nuaim L, Al-Jabari A, et al. Abdomino-pelvic packing to control severe haemorrhage following caesarean hysterectomy. J Obstet Gynaecol 1999; 19:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/24\">",
"      Awonuga AO, Merhi ZO, Khulpateea N. Abdominal packing for intractable obstetrical and gynecologic hemorrhage. Int J Gynaecol Obstet 2006; 93:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/25\">",
"      Howard RJ, Straughn JM Jr, Huh WK, Rouse DJ. Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. Obstet Gynecol 2002; 100:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/26\">",
"      Burchell RC. The umbrella pack to control pelvic hemorrhage. Conn Med 1968; 32:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/27\">",
"      PARENTE JT, DLUGI H, WEINGOLD AB. Pelvic hemostasis: a new technic and pack. Obstet Gynecol 1962; 19:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/28\">",
"      Cassels JW Jr, Greenberg H, Otterson WN. Pelvic tamponade in puerperal hemorrhage. A case report. J Reprod Med 1985; 30:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/29\">",
"      Robie GF, Morgan MA, Payne GG Jr, Wasemiller-Smith L. Logothetopulos pack for the management of uncontrollable postpartum hemorrhage. Am J Perinatol 1990; 7:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/30\">",
"      Hallak M, Dildy GA 3rd, Hurley TJ, Moise KJ Jr. Transvaginal pressure pack for life-threatening pelvic hemorrhage secondary to placenta accreta. Obstet Gynecol 1991; 78:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/31\">",
"      Dildy, GA, Scott, JR, Saffer, CS, Belfort, MA. Pelvic pressure pack for catastrophic postpartum hemorrhage. Obstet Gynecol 2000; 95:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/32\">",
"      Briery CM, Rose CH, Hudson WT, et al. Planned vs emergent cesarean hysterectomy. Am J Obstet Gynecol 2007; 197:154.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29367/abstract/33\">",
"      Wright JD, Devine P, Shah M, et al. Morbidity and mortality of peripartum hysterectomy. Obstet Gynecol 2010; 115:1187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5395 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29367=[""].join("\n");
var outline_f28_43_29367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DECISION MAKING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OPERATIVE PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2976705591\">",
"      Exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Evaluation of bladder and ureteral integrity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Key points",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTROL OF PERSISTENT PELVIC BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hemostatic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pelvic packing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pack removal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5395|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/17/18712\" title=\"figure 1\">",
"      Transection of round ligaments during peripartum hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/21/16731\" title=\"table 1\">",
"      Types peripartum hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23166\" title=\"table 2\">",
"      Steps in management of postpartum hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25094?source=related_link\">",
"      Fibrin sealant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_43_29368="Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis";
var content_f28_43_29368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Clare Hutchinson, MDCM, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Brian M Feldman, MD, MSc, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29368/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/43/29368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile dermatomyositis (JDM) and juvenile polymyositis (JPM) are rare autoimmune myopathies in childhood. JDM is primarily a capillary vasculopathy, whereas JPM involves direct T-cell invasion of muscle fibers similar to that seen in adult polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and clinical manifestations of JDM and JPM will be reviewed here. Diagnosis and treatment of these disorders are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31079?source=see_link\">",
"     \"Diagnosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=see_link\">",
"     \"Treatment and prognosis of juvenile dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;JDM is the most common idiopathic inflammatory myopathy of childhood accounting for approximately 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In population-based studies, JDM has a reported annual incidence that ranges from two to four cases per one million children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. The peak incidence is from 5 to 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Girls are affected more often than boys with a two- to five-fold greater rate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/7,8,10\">",
"     7,8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    JPM occurs less frequently and accounts for only 3 to 6 percent of childhood idiopathic inflammatory myopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the etiology remains unclear, it has been proposed that JDM and JPM are caused by an autoimmune reaction in genetically susceptible individuals, possibly in response to environmental triggers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of JPM and JDM in monozygotic twins and first-degree relatives suggests a genetic predisposition to these disorders in some families [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Certain HLA alleles also have been reported to be more common in patients with JDM; these include HLA-B8, HLA-DQA1*0501 and HLA-DQA1*0301 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. However, investigation of HLA class II alleles in patients with JDM has not identified any disease-associated allele [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-HLA associated genes, including genetic polymorphisms in tumor necrosis factor-alpha and interleukin-1 receptor antagonist, are known risk factors for the development of JDM or for the severity of its presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A significantly increased rate of autoimmune diseases, particularly systemic lupus erythematosus (SLE) and type 1 diabetes, is seen in family members of children with JDM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/20\">",
"     20",
"    </a>",
"    ]. Higher levels of interferon-alpha were seen in children with JDM who had family members with SLE, suggesting a shared predisposing factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Immunologic mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings support the role of the immune system in the pathogenesis of JDM and JPM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cell invasion of muscle fibers in patients with JPM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased mast cell numbers in the skin and mature plasmacytoid dendritic cells in both muscle and skin in patients with JDM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antinuclear antibodies are present in about 70 percent of patients with JDM and JPM. The specific antigen(s) for these antibodies have not yet been identified [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Myositis-specific autoantibodies (MSAs) are found in a minority of adults with DM and PM and are associated with specific clinical subgroups. However, MSAs have been identified in only a small number of children with inflammatory myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In one study of 38 children with JDM and other connective tissue diseases, MSAs were identified in 12 of 77 serum samples [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/23\">",
"       23",
"      </a>",
"      ]. In a second study, MSAs (specifically anti Mi-2 autoantibodies) were found in only 2 of 42 patients with JDM. A study of 116 children registered in the UK and Ireland JDM National Registry and Repository showed a 23 percent prevalence of",
"      <span class=\"nowrap\">",
"       anti-p155/140",
"      </span>",
"      antibodies; children with positive antibodies had more extensive skin disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-melanoma differentiation-associated gene 5 antibodies are associated with the occurrence of interstitial lung disease in patients with JDM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/26\">",
"       26",
"      </a>",
"      ]. Appearance of these antibodies may precede clinical signs of interstitial lung disease.",
"     </li>",
"     <li>",
"      Similarity of observed histologic changes between JDM and chronic graft-versus-host disease. The presence of persistent maternal cells (maternal microchimerism), which triggers an immunologic response, has been proposed as a common pathogenetic pathway for the two disorders. Two studies have reported evidence of maternal microchimerism in the peripheral blood and muscle biopsies of boys with juvenile inflammatory myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Experimental data demonstrating increased T cell reactivity of in vitro peripheral blood mononuclear cells to heat shock protein (HSP) 60 in patients compared to normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/29\">",
"       29",
"      </a>",
"      ]. HSPs have been proposed to have a regulatory role in chronic inflammatory diseases and may be an autoantigen for these disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39994?source=see_link&amp;anchor=H25#H25\">",
"       \"Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis\", section on 'Gamma-delta-T cells'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations have suggested that JDM may develop as an unusual response to infection in a genetically susceptible host:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an increased prevalence of Coxsackie B antibodies in children with JDM compared to matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Case reports of viral isolation from muscle specimens in adult myositis have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is an association between echovirus infection and chronic polymyositis in children with agammaglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A seasonal variation of onset in JDM exists, with clustering of cases in the spring and summer [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epitopes that are common both to human skeletal muscle and the bacteria Streptococcus pyogenes have been shown to be targets for cytotoxic T cell responses in patients with early, active JDM, indicating a possible link between an immune response to bacteria and the development of myositis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory and gastrointestinal complaints",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      antibiotic use are common in the three months before diagnosis of JDM [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, attempts at demonstrating a viral etiology of JDM have failed. As an example, a study of 79 patients with new onset JDM found normal antibody titers to Herpes simplex virus, Coxsackievirus B 1 through 6, and Toxoplasma gondii [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/37\">",
"     37",
"    </a>",
"    ]. Another report using the polymerase chain reaction was unable to demonstrate evidence of viral genetic material in the muscle of 20 individuals with active, untreated recent onset JDM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike adults, children with JDM or JPM do not have an increased risk of malignancy. In one Scottish population-based study, for example, cancer was not observed among 35 and 9 children with JDM or JPM, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/39\">",
"     39",
"    </a>",
"    ]. There are rare case reports of solid tumors or hematologic malignancies in children with JDM; however, nothing suggests that the incidence of these disorders is greater than in the general population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=see_link\">",
"     \"Malignancy in dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data, unless the presenting features are quite unusual, a search for malignancy does not need to be made when children present with idiopathic inflammatory myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness is the hallmark of JDM and JPM. In addition, patients with JDM present with characteristic rashes (",
"    <a class=\"graphic graphic_picture graphicRef52062 \" href=\"UTD.htm?8/3/8243\">",
"     picture 1",
"    </a>",
"    ). Children with JDM and JPM also may have constitutional symptoms (fever, weight loss, fatigue, and headache), which may be the initial finding prior to the onset of muscle weakness, and in patients with JDM, rash.",
"   </p>",
"   <p>",
"    Because JPM is a rare entity, there is little descriptive clinical information about this disorder. This discussion will mainly focus on the clinical manifestations of JDM.",
"   </p>",
"   <p>",
"    The clinical presentation of JDM varies and is exemplified by the two following case series. In the first review from a single tertiary Canadian center of 105 patients with JDM (mean age at diagnosis 7.6 years), the most common",
"    <span class=\"nowrap\">",
"     symptoms/findings",
"    </span>",
"    and their frequency were noted at disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gottron's rash: 91 percent",
"     </li>",
"     <li>",
"      Heliotrope rash: 83 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Malar/facial",
"      </span>",
"      rash: 42 percent",
"     </li>",
"     <li>",
"      Nailfold capillary change: 80 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Myalgia/arthralgia:",
"      </span>",
"      25 percent",
"     </li>",
"     <li>",
"      Dysphonia or dysphagia: 24 percent",
"     </li>",
"     <li>",
"      Anorexia: 18 percent",
"     </li>",
"     <li>",
"      Fever: 16 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second case series is from the JDM Research Registry and included 166 newly diagnosed children living in the continental United States from 1994 to 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/10\">",
"     10",
"    </a>",
"    ]. The mean age of diagnosis was 7.5 &plusmn; 3.8 years, and the median duration of symptoms prior to diagnosis was four months. There was no difference in the age of diagnosis or duration of untreated disease based upon gender or ethnicity. The initial symptoms were rash in 65 percent, weakness alone in 29 percent, or both rash and weakness in 6 percent of patients. The severity of the weakness increased with the duration of symptoms prior to diagnosis. Both the height and weight were lower compared to normative data from the National Health and Nutrition Examination Study (NHANES) III survey. Other findings included capillary dilation, arthritis, difficulty swallowing, abdominal pain, and fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous manifestations are common in children with JDM and include a characteristic heliotrope rash, Gottron&rsquo;s papules, nailfold capillary changes, calcinosis, and skin ulcerations (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several distinct rashes (ie, heliotrope rash and Gottron's papules) may occur simultaneously with muscle involvement but can also be prominent prior to obvious muscular weakness. Rash is an important distinguishing feature between JDM and JPM, as it is not present in the latter condition. Skin disease may be exacerbated by exposure to sunlight and, as such, sun protection should be part of routine care in JDM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heliotrope dermatitis is a reddish-purple rash on the upper eyelids, often accompanied by swelling of the eyelid (",
"      <a class=\"graphic graphic_picture graphicRef52062 \" href=\"UTD.htm?8/3/8243\">",
"       picture 1",
"      </a>",
"      ). Malar and facial erythema may also be present. Heliotrope rash is one of the most common findings in patients with JDM, with a reported rate of 83 percent in the previously mentioned Canadian study, and a 94 percent rate in 44 patients from Hungary [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/4,41\">",
"       4,41",
"      </a>",
"      ]. Periorbital edema, upper lid edema, or telangiectasia of the eyelid capillaries can be seen in 50 to 90 percent of children [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/42,43\">",
"       42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gottron's papules are an erythematous, papulosquamous eruption over the dorsal surfaces of the knuckles (",
"      <a class=\"graphic graphic_picture graphicRef52062 \" href=\"UTD.htm?8/3/8243\">",
"       picture 1",
"      </a>",
"      ). The term \"Gottron's sign\" is often used if the lesions are not papular. Similar lesions can occur over the extensor aspects of the elbows, knees, and medial malleoli, at times mimicking psoriasis. Gottron's papules are a common feature in patients with JDM, with a reported rate of 91 percent of Canadian and 77 percent of Hungarian patients from the previously mentioned studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/4,41\">",
"       4,41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Nailfold capillary changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nailfold capillary changes may be observed at the bedside or in clinic. These include capillary dilatation, tortuosity and dropout. The measured density of",
"    <span class=\"nowrap\">",
"     capillaries/mm",
"    </span>",
"    may be a useful tool for monitoring clinical activity in JDM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], as shown in panel C (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Skin ulcerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative skin disease is a serious and potentially life-threatening manifestation of JDM, as shown in panel E (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ). Ulcers presumably reflect significant vasculopathy in the skin (with tissue hypoxia and necrosis), and may signal vasculopathy in other organs (especially the lungs and gut). Patients with ulcerative lesions have more severe disease and a worse prognosis.",
"   </p>",
"   <p>",
"    This was illustrated by a retrospective case series that included 6 of 47 children with JDM with extensive ulcerative skin vasculitis present at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/46\">",
"     46",
"    </a>",
"    ]. These six patients continued to have persistent muscle weakness, elevations of muscle enzyme activity, and severe generalized cutaneous vasculitis despite receiving corticosteroid therapy. In another study, 10 of 29 patients had a chronic disease course characterized by ulcerative cutaneous and gastrointestinal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/47\">",
"     47",
"    </a>",
"    ]. Two of the 10 died due to complications including gastrointestinal perforation, five had severe musculoskeletal and cutaneous damage, and three had no residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Calcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystrophic calcification or calcinosis (soft tissue calcification) generally develops within a few years of diagnosis, as shown in panel D (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/3,48\">",
"     3,48",
"    </a>",
"    ]. Reports of its prevalence vary from 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/46,49\">",
"     46,49",
"    </a>",
"    ]. In contrast, one study of 144 patients from the United Kingdom reported a much lower calcinosis rate of 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five distinct patterns of calcinosis have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/46,50\">",
"     46,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small, scattered, superficial plaques or nodules, usually on the extremities. These lesions often do not interfere with function, but may be painful and may develop spontaneous cellulitis-like inflammation (sometimes with drainage of toothpaste-like calcium soap). Inflamed superficial calcinosis must be differentiated from superinfected lesions. Superficial calcinosis often regresses spontaneously over a period of years.",
"     </li>",
"     <li>",
"      Deep tumoral muscle calcification often found in the proximal muscle groups that may interfere with joint motion. These deposits may ulcerate or extrude calcific material through the skin. These may require surgical debridement in order to maximize joint function.",
"     </li>",
"     <li>",
"      Diffuse deposits along myofascial planes that may limit joint motion and may be painful.",
"     </li>",
"     <li>",
"      Mixed forms of the above three types may be seen.",
"     </li>",
"     <li>",
"      Extensive exoskeleton-like calcium deposits that result in serious limitations in function. Patients with this form of calcinosis often have a history of a severe, unremitting disease course associated with ulcerative cutaneous disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcinosis has been associated with the following risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delay in diagnosis or treatment, or inadequate treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/46,51\">",
"       46,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tissue necrosis factor (TNF) alpha-308A genotype (this allele is associated with increased levels of TNF alpha) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients below five years of age have been reported to be more likely to develop calcinosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/52\">",
"       52",
"      </a>",
"      ]. However, another study found no association between age of onset of JDM and calcinosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Amyopathic dermatomyositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous manifestations of JDM may appear in the absence of clinically apparent muscle disease in a small number of children. Children with this presentation, termed amyopathic JDM, may never develop muscle weakness, but amyopathic JDM may reflect an early phase in the disease course before muscle weakness has yet developed. The skin findings may require therapy but may remit in some without systemic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, all such children require evaluation by an experienced pediatric rheumatologist or neurologist to assure that they are not, in fact, weak. We feel that children with muscle enzyme elevation, or other evidence of subclinical muscle inflammation, should be treated, regardless of whether or not clinically evident weakness is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory myopathies are characterized by symmetric, proximal muscle weakness. This may present with functional limitations, such as difficulty getting up from the floor, getting into and out of motor vehicles, or climbing stairs. Washing or grooming hair may pose a challenge, and severely affected children may not be able to feed themselves. In very young children, frequent falls may be an important symptom. A Gower's sign is frequently present.",
"   </p>",
"   <p>",
"    Weakness of the palate and cricopharyngeal muscle may result in problems swallowing, a nasal voice, tracheal aspiration, and reflux of food into the nasopharynx. Involvement of the upper esophagus can lead to dysphagia for solids and liquids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-erosive arthralgia and arthritis may be present at the time of diagnosis or during the disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/3,4,56\">",
"     3,4,56",
"    </a>",
"    ]. Contractures may be seen but are usually related to muscle inflammation rather than arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired lipodystrophy, as shown in panel F (",
"    <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"     picture 2",
"    </a>",
"    ), and associated metabolic abnormalities such as insulin resistance, acanthosis nigricans, and type 2 diabetes are being increasingly recognized in patients with JDM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/57\">",
"     57",
"    </a>",
"    ]. In a study of 20 patients with JDM, 4 were found to have lipodystrophy accompanied by either insulin resistance or type 2 diabetes, while an additional 13 had glucose and lipid abnormalities without evidence of lipodystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/58\">",
"     58",
"    </a>",
"    ]. In another study of 20 patients, 13 patients had lipoatrophy based upon subcutaneous fat quantification by skinfold caliper including 8 patients with physical findings of lipodystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/59\">",
"     59",
"    </a>",
"    ]. Oral glucose tests were normal in all patients, but 12 of 18 patients tested were found to have hypertriglyceridemia.",
"   </p>",
"   <p>",
"    JDM appears to be a common cause of lipodystrophy in children. In a retrospective review, JDM alone or in association with another autoimmune disease (eg, juvenile idiopathic arthritis) was the underlying disease in 18 of 23 children with acquired lipodystrophy. Other findings included acanthosis nigricans (n = 5 patients), hyperpigmentation (n = 5), elevated liver enzymes (n = 5), and hypertension (n =3) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical manifestations of JDM include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary involvement &mdash; Pulmonary manifestations are much less common in children than adults, but interstitial lung disease may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gastrointestinal vasculopathy &mdash; Gastrointestinal (GI) tract involvement is relatively rare, but can be life-threatening. Affected patients may present with abdominal pain, pneumatosis intestinalis, gastrointestinal bleeding, or perforation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/2,62\">",
"       2,62",
"      </a>",
"      ]. Acute GI vasculitis and chronic abdominal endarteropathy have been described in patients with JDM, indicating that the underlying pathology leading to ulceration and perforation of the intestines is complex [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/63\">",
"       63",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Any patient with JDM experiencing abdominal pain that persists or progresses warrants careful investigation because GI vasculopathy may occur late in the disease course or in a patient with only mild myositis. Of note, abdominal radiographs and stool testing for occult blood may be normal in patients with GI involvement. The need for further investigation, such as abdominal ultrasonography or computed tomography (CT), must be guided by clinical suspicion for significant GI involvement.",
"     </li>",
"     <li>",
"      Anasarca &mdash; The presence of anasarca at presentation may be a poor prognostic sign indicating severe disease that may respond very slowly to treatment and may not respond to corticosteroids alone. The generalized edema may be the result of a diffuse capillary leak resulting from vascular endothelial damage [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29368/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile dermatomyositis (JDM) and juvenile polymyositis (JPM) are rare autoimmune myopathies affecting children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      JDM is the most common of these disorders accounting for 85 percent of cases with a reported incidence that ranges from two to four cases per million children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the etiology of JDM and JPM remains unclear, it has been proposed that these disorders are caused by an autoimmune reaction within the muscle tissue of genetically susceptible individuals, possibly in response to environmental triggers. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symmetrical proximal muscle weakness is the hallmark clinical feature of these two disorders. In addition, heliotrope rash (reddish-purple rash on the upper eyelids, often accompanied by swelling of the eyelid) (",
"      <a class=\"graphic graphic_picture graphicRef52062 \" href=\"UTD.htm?8/3/8243\">",
"       picture 1",
"      </a>",
"      ) and Gottron's papules (erythematous, papulosquamous eruption over the dorsal surfaces of the knuckles) (",
"      <a class=\"graphic graphic_picture graphicRef52062 \" href=\"UTD.htm?8/3/8243\">",
"       picture 1",
"      </a>",
"      ) are characteristic rashes of JDM. Children with JDM and JPM also may have constitutional symptoms (fever, weight loss, fatigue, and headache), which may be the initial finding prior to the onset of muscle weakness, and in patients with JDM, rash.",
"     </li>",
"     <li>",
"      Other clinical manifestations include nailfold capillary changes, skin ulcerations, calcinosis (soft tissue calcification), non-erosive arthralgia and arthritis, lipodystrophy, and insulin resistance (",
"      <a class=\"graphic graphic_picture graphicRef63190 \" href=\"UTD.htm?0/23/377\">",
"       picture 2",
"      </a>",
"      ). Gastrointestinal vasculopathy is a relative rare, but life-threatening manifestation that may present as abdominal pain, pneumatosis intestinalis, gastrointestinal bleeding, or perforation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/1\">",
"      Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/2\">",
"      Banker BQ, Victor M. Dermatomyositis (systemic angiopathy) of childhood. Medicine (Baltimore) 1966; 45:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/3\">",
"      McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/4\">",
"      Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002; 28:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/5\">",
"      Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/6\">",
"      Pelkonen PM, Jalanko HJ, Lantto RK, et al. Incidence of systemic connective tissue diseases in children: a nationwide prospective study in Finland. J Rheumatol 1994; 21:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/7\">",
"      Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol 1995; 34:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/8\">",
"      Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/9\">",
"      Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Sch&ouml;nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/10\">",
"      Pachman LM, Abbott K, Sinacore JM, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/11\">",
"      Harati Y, Niakan E, Bergman EW. Childhood dermatomyositis in monozygotic twins. Neurology 1986; 36:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/12\">",
"      LEONHARDT T. Familial occurrence of collagen diseases. II. Progressive systemic sclerosis and dermatomyositis. Acta Med Scand 1961; 169:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/13\">",
"      Mamyrova G, O'Hanlon TP, Monroe JB, et al. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006; 54:3979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/14\">",
"      Pachman LM, Jonasson O, Cannon RA, Friedman JM. Increased frequency of HLA-B8 in juvenile dermatomyositis. Lancet 1977; 2:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/15\">",
"      Reed AM, Pachman LM, Hayford J, Ober C. Immunogenetic studies in families of children with juvenile dermatomyositis. J Rheumatol 1998; 25:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/16\">",
"      Vavrincov&aacute; P, Havelka S, Cerna M, Stastny P. HLA class II alleles in juvenile dermatomyositis. J Rheumatol Suppl 1993; 37:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/17\">",
"      Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000; 43:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/18\">",
"      Rider LG, Artlett CM, Foster CB, et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 2000; 121:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/19\">",
"      Mamyrova G, O'Hanlon TP, Sillers L, et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008; 58:3941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/20\">",
"      Niewold TB, Wu SC, Smith M, et al. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics 2011; 127:e1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/21\">",
"      Shrestha S, Wershil B, Sarwark JF, et al. Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. Arthritis Rheum 2010; 62:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/22\">",
"      Pachman LM. Inflammatory myopathy in children. Rheum Dis Clin North Am 1994; 20:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/23\">",
"      Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum 1994; 37:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/24\">",
"      Feldman BM, Reichlin M, Laxer RM, et al. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol 1996; 23:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/25\">",
"      Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/26\">",
"      Kobayashi I, Okura Y, Yamada M, et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011; 158:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/27\">",
"      Artlett CM, Ramos R, Jiminez SA, et al. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 2000; 356:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/28\">",
"      Reed AM, Picornell YJ, Harwood A, Kredich DW. Chimerism in children with juvenile dermatomyositis. Lancet 2000; 356:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/29\">",
"      Elst EF, Klein M, de Jager W, et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008; 58:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/30\">",
"      Christensen ML, Pachman LM, Schneiderman R, et al. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum 1986; 29:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/31\">",
"      Tang TT, Sedmak GV, Siegesmund KA, McCreadie SR. Chronic myopathy associated with coxsackievirus type A9. A combined electron microscopical and viral isolation study. N Engl J Med 1975; 292:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/32\">",
"      Webster AD, Tripp JH, Hayward AR, et al. Echovirus encephalitis and myositis in primary immunoglobulin deficiency. Arch Dis Child 1978; 53:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/33\">",
"      Pachman LM, Hayford JR, Hochberg MC. Seasonal onset in juvenile dermatomyositis (JDMS): an epidemiological study. Arthritis Rheum 1992; 35:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/34\">",
"      Massa M, Costouros N, Mazzoli F, et al. Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum 2002; 46:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/35\">",
"      Pachman LM, Lipton R, Ramsey-Goldman R, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005; 53:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/36\">",
"      Manlhiot C, Liang L, Tran D, et al. Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset. Rheumatology (Oxford) 2008; 47:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/37\">",
"      Pachman LM, Hayford JR, Hochberg MC, et al. New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/38\">",
"      Pachman LM, Litt DL, Rowley AH, et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthritis Rheum 1995; 38:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/39\">",
"      Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001; 85:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/40\">",
"      Dugan EM, Huber AM, Miller FW, et al. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/41\">",
"      Constantin T, Ponyi A, Orb&aacute;n I, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity 2006; 39:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/42\">",
"      Akikusa JD, Tennankore DK, Levin AV, Feldman BM. Eye findings in patients with juvenile dermatomyositis. J Rheumatol 2005; 32:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/43\">",
"      COOK CD, ROSEN FS, BANKER BQ. DERMATOMYOSITIS AND FOCAL SCLERODERMA. Pediatr Clin North Am 1963; 10:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/44\">",
"      Smith RL, Sundberg J, Shamiyah E, et al. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/45\">",
"      Schmeling H, Stephens S, Goia C, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford) 2011; 50:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/46\">",
"      Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/47\">",
"      Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum 1982; 25:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/48\">",
"      Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/49\">",
"      Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J) 2008; 84:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/50\">",
"      Blane CE, White SJ, Braunstein EM, et al. Patterns of calcification in childhood dermatomyositis. AJR Am J Roentgenol 1984; 142:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/51\">",
"      Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/52\">",
"      Marhaug G, Shah V, Shroff R, et al. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/53\">",
"      Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993; 100:124S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/54\">",
"      Plamondon S, Dent PB. Juvenile amyopathic dermatomyositis: results of a case finding descriptive survey. J Rheumatol 2000; 27:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/55\">",
"      Stonecipher MR, Jorizzo JL, White WL, et al. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis? J Am Acad Dermatol 1993; 28:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/56\">",
"      Tse S, Lubelsky S, Gordon M, et al. The arthritis of inflammatory childhood myositis syndromes. J Rheumatol 2001; 28:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/57\">",
"      Bingham A, Mamyrova G, Rother KI, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine (Baltimore) 2008; 87:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/58\">",
"      Huemer C, Kitson H, Malleson PN, et al. Lipodystrophy in patients with juvenile dermatomyositis--evaluation of clinical and metabolic abnormalities. J Rheumatol 2001; 28:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/59\">",
"      Verma S, Singh S, Bhalla AK, Khullar M. Study of subcutaneous fat in children with juvenile dermatomyositis. Arthritis Rheum 2006; 55:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/60\">",
"      Pope E, Janson A, Khambalia A, Feldman B. Childhood acquired lipodystrophy: a retrospective study. J Am Acad Dermatol 2006; 55:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/61\">",
"      Kobayashi I, Yamada M, Takahashi Y, et al. Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003; 42:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/62\">",
"      Downey EC Jr, Woolley MM, Hanson V. Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg 1988; 123:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/63\">",
"      Mamyrova G, Kleiner DE, James-Newton L, et al. Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis Rheum 2007; 57:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29368/abstract/64\">",
"      Mitchell JP, Dennis GJ, Rider LG. Juvenile dermatomyositis presenting with anasarca: A possible indicator of severe disease activity. J Pediatr 2001; 138:942.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6419 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29368=[""].join("\n");
var outline_f28_43_29368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Immunologic mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rash",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Nailfold capillary changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Skin ulcerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Calcinosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Amyopathic dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6419\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6419|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/3/8243\" title=\"picture 1\">",
"      Rash - Juvenile dermatomyositis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/23/377\" title=\"picture 2\">",
"      Physical findings - Juvenile dermatomyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31079?source=related_link\">",
"      Diagnosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39994?source=related_link\">",
"      Juvenile idiopathic arthritis: Epidemiology and immunopathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38566?source=related_link\">",
"      Malignancy in dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/5/2138?source=related_link\">",
"      Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_43_29369="Treatment of unilateral atherosclerotic renal artery stenosis";
var content_f28_43_29369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of unilateral atherosclerotic renal artery stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29369/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29369/contributors\">",
"     Stephen Textor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29369/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29369/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29369/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29369/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/43/29369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal artery stenosis is a relatively common finding in older patients with hypertension. However, renal artery stenosis is the primary cause of hypertension (ie, renovascular hypertension) only in certain settings.",
"   </p>",
"   <p>",
"    In most cases of renal artery stenosis, one kidney is affected with the second kidney being essentially normal, hence the designation, \"unilateral\" disease. Individuals with high-grade stenosis to both kidneys, or to a solitary functioning kidney thereby affecting the entire functioning renal mass, are considered to have \"bilateral\" disease.",
"   </p>",
"   <p>",
"    The treatment of unilateral atherosclerotic renal artery stenosis will be reviewed here. Clinical clues suggesting the presence of renovascular hypertension and establishing the diagnosis of renal artery stenosis, treatment of bilateral atherosclerotic renal artery stenosis, issues related to chronic kidney disease associated with atherosclerotic renovascular disease, and diagnosis and treatment of fibromuscular disease are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromuscular dysplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=see_link\">",
"     \"Treatment of fibromuscular dysplasia of the renal arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5462347\">",
"    <span class=\"h1\">",
"     BRIEF REVIEW OF PRESENTATION AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5462354\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of renovascular hypertension is probably less than 1 percent in patients with mild hypertension but may be as high as 10 to 40 percent in patients with acute (even if superimposed on a preexisting elevation in blood pressure), severe, or refractory hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link&amp;anchor=H3#H3\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\", section on 'Clinical clues for renovascular hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In two prospective treatment trials of patients with renal artery stenosis, the prevalence of unilateral disease (compared with bilateral disease) ranged from 53 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Most patients with unilateral renal artery stenosis can be managed with antihypertensive drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5462401\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major causes of unilateral renal artery stenosis: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atherosclerosis &ndash; Atherosclerosis primarily affects patients (particularly men) over the age of 45 years and usually involves the aortic orifice or the proximal main renal artery. This disorder is particularly common in patients with diffuse atherosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/4\">",
"       4",
"      </a>",
"      ] but can occur as a relatively isolated renal lesion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H3#H3\">",
"       \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Association with systemic atherosclerosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia &ndash; In contrast to atherosclerosis, fibromuscular dysplasia (FMD) most often affects women under the age of 50 years and typically involves the distal main renal artery or the intrarenal branches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromuscular dysplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=see_link\">",
"       \"Treatment of fibromuscular dysplasia of the renal arteries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Clinical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical findings that suggest an increased likelihood of secondary hypertension, some of which specifically suggest the presence of renovascular disease. These findings are used clinically to determine which patients should be evaluated for renovascular disease (",
"    <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"     table 1",
"    </a>",
"    ). Some of these clues are relatively specific for the presence of renovascular disease, and some help to identify those patients who are more likely to benefit from intervention. These clinical clues, as well as the indications for testing to establish the diagnosis of renal artery stenosis, are presented in detail in other topics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"     \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H517662#H517662\">",
"     \"Establishing the diagnosis of renovascular hypertension\", section on 'Indications for testing'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Advances in contrast imaging (computed tomography [CT] and magnetic resonance [MR] angiography) and Doppler ultrasound have led to the identification of renal arterial stenoses as an \"incidental finding\" more commonly than before [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/5\">",
"     5",
"    </a>",
"    ]. The absence of clinical clues for renovascular hypertension in such patients substantially reduces the likelihood that the renal artery stenosis is responsible for hypertension, if present, and also reduces the likelihood of benefit from percutaneous or surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H16699645#H16699645\">",
"     \"Establishing the diagnosis of renovascular hypertension\", section on 'Incidental lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of unilateral renal artery stenosis is made by imaging studies in patients thought to be at risk. With duplex Doppler ultrasonography, a peak systolic velocity above 200",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    suggests a stenosis of greater than 60 percent, although some studies indicate that a peak systolic velocity above 300",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    represents a hemodynamically important threshold. With computed tomography and MR angiography, a stenosis greater than 75 percent in one or both renal arteries, or a 50 percent stenosis with poststenotic dilatation, suggests that the patient may have renovascular hypertension. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link\">",
"     \"Establishing the diagnosis of renovascular hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTOR REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atherosclerotic renovascular disease have a high rate of systemic atherosclerosis and are at increased risk for adverse cardiovascular outcomes. As a result, they are considered to have a coronary artery disease equivalent and should be treated according to current guidelines for secondary prevention of cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5462582\">",
"    <span class=\"h2\">",
"     General approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient who has a high probability of having renovascular hypertension (based upon clinical clues) is diagnosed with renal artery stenosis, there are three therapeutic options available:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical therapy (essentially all patients)",
"     </li>",
"     <li>",
"      Percutaneous angioplasty with or without stent placement",
"     </li>",
"     <li>",
"      Surgical revascularization or, in some cases, resection of a \"pressor\" kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest the following approach in patients with unilateral atherosclerotic renal artery stenosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical therapy for control of hypertension in",
"      <strong>",
"       all",
"      </strong>",
"      patients with unilateral renal artery stenosis",
"     </li>",
"     <li>",
"      Revascularization, usually by percutaneous angioplasty with stenting (or surgical revascularization in patients with complex anatomic lesions), is reasonable in patients who have a",
"      <strong>",
"       high likelihood",
"      </strong>",
"      of benefitting from intervention. The following scenarios identify such patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A short duration of blood pressure elevation prior to the diagnosis of renovascular disease, since this is the strongest clinical predictor of a fall in blood pressure after renal revascularization",
"     </li>",
"     <li>",
"      Failure of optimal medical therapy to control the blood pressure",
"     </li>",
"     <li>",
"      Intolerance to optimal medical therapy",
"     </li>",
"     <li>",
"      Recurrent flash pulmonary edema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refractory heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our suggestions presented above are broadly consistent with the 2006 American College of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC)/American",
"    </span>",
"    Heart Association (AHA) guidelines on peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above suggestions apply to unilateral atherosclerotic renal artery stenosis. Our suggestions for treatment of bilateral atherosclerotic renal artery stenosis and fibromuscular dysplasia (FMD) are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=see_link\">",
"     \"Treatment of fibromuscular dysplasia of the renal arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5462771\">",
"    <span class=\"h2\">",
"     Revascularization versus medical therapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revascularization using angioplasty with or without stent in combination with medical therapy has been compared with medical therapy alone in seven randomized trials that included patients with unilateral atherosclerotic renal artery stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/2,3,7-11\">",
"     2,3,7-11",
"    </a>",
"    ]. A 2011 meta-analysis included six of these seven trials with data on a total of 1208 patients, most of whom came from the single largest trial (ASTRAL) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients treated with percutaneous transluminal renal angioplasty (PTRA) with or without stent required an average of 0.3 fewer antihypertensive medications. However, there was no difference between the two groups with regard to attained blood pressure, change in renal function, or the incidence of heart failure, stroke, or total mortality. Periprocedural complications associated with PTRA ranged from 7 to 31 percent, with four procedure-related deaths and 12 renal artery perforations or dissections. Thus, other than a slight reduction in the number of antihypertensive medications used, none of these studies demonstrated an important clinical benefit from PTRA.",
"   </p>",
"   <p>",
"    In the largest trial (ASTRAL), PTRA plus stent placement was compared with medical therapy in 806 patients who had atherosclerotic renovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/2\">",
"     2",
"    </a>",
"    ]. There was no significant difference between the two groups for any endpoint, including blood pressure, progression of renal disease, cardiovascular events, or mortality. The results of the ASTRAL trial are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Stent placement and outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, two major criticisms are applicable to each of these seven trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Considerable selection bias",
"      </strong>",
"      ��� For the most part, the patients enrolled in these trials did",
"      <strong>",
"       not",
"      </strong>",
"      meet the criteria for selecting patients likely to benefit from intervention (eg, short duration of blood pressure elevation, hypertension resistant to medical therapy, recurrent flash pulmonary edema). In ASTRAL, for example, many patients had stenoses that were probably not clinically significant (50 to 70 percent), and patients were excluded if their primary doctors felt that they \"definitely\" needed revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Results of the trials differ substantially from observational reports",
"      </strong>",
"      ��� For the most part, patients selected by their treating physicians to undergo revascularization have derived greater benefit from revascularization than did patients enrolled in the trials who were randomly assigned to revascularization. This finding may be related to the selection bias associated with each of the trials, as mentioned above. The following examples are illustrative:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An observational study compared the outcomes of 347 patients with renal artery stenosis treated with medical therapy alone with 89 patients treated with PTRA [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/14\">",
"       14",
"      </a>",
"      ]. Of these 89 patients, most underwent revascularization because of specific indications (eg, refractory hypertension, flash pulmonary edema, intolerance to angiotensin inhibition), whereas the remainder had PTRA because they were enrolled in a randomized trial. The patients who underwent revascularization had more comorbidity at baseline than patients who received medical therapy alone. Despite this, patients who had revascularization had significantly lower rates of mortality and renal disease progression after multivariable analysis.",
"     </li>",
"     <li>",
"      In another study, 39 patients who underwent PTRA with stent for refractory heart failure were followed for a mean of 21 months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/15\">",
"       15",
"      </a>",
"      ]. After stenting, there were significant declines in blood pressure (from",
"      <span class=\"nowrap\">",
"       174/85",
"      </span>",
"      to",
"      <span class=\"nowrap\">",
"       148/72",
"      </span>",
"      mmHg), New York Heart Association (NYHA) functional class (from 2.9 to 1.6), and number of annual hospitalizations for heart failure (from 2.4 to 0.3 per year). In addition, the mean serum creatinine significantly decreased (from 3.2 to 2.6",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, for patients with unilateral atherosclerotic renal artery stenosis who have characteristics similar to those enrolled in the trials, there are high quality data that PTRA provides no additional benefit to medical therapy and increases the risk of adverse events. In contrast, for patients who have specific characteristics (described immediately below), there are low quality data that PTRA plus medical therapy is superior to medical therapy alone.",
"   </p>",
"   <p>",
"    The specific characteristics that identify patients who may benefit from revascularization include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A short duration of blood pressure elevation prior to the diagnosis of renovascular disease",
"     </li>",
"     <li>",
"      Failure of optimal medical therapy to control the blood pressure",
"     </li>",
"     <li>",
"      Intolerance to optimal medical therapy",
"     </li>",
"     <li>",
"      Recurrent flash pulmonary edema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refractory heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5463575\">",
"    <span class=\"h2\">",
"     Overview of therapeutic options",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three therapeutic options available:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical therapy",
"     </li>",
"     <li>",
"      Percutaneous angioplasty with or without stent placement",
"     </li>",
"     <li>",
"      Surgical revascularization or, in some cases, resection of a \"pressor\" kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) has markedly improved the ability to control the blood pressure in patients with renovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. If goal blood pressure is not reached with angiotensin inhibition alone, other antihypertensive drugs, such as a thiazide diuretic (preferably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ), a long-acting calcium channel blocker, an aldosterone antagonist, or a beta blocker, should be added as necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/6,16\">",
"     6,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H5#H5\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Chlorthalidone versus hydrochlorothiazide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, a number of potential concerns with medical treatment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Progression of the stenosis and vascular occlusion",
"     </li>",
"     <li>",
"      Impaired kidney function with angiotensin inhibition",
"     </li>",
"     <li>",
"      Long-term ischemic damage in the stenotic kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Progression of stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;One concern with using medical therapy alone to treat patients with renal artery stenosis is progression of the stenotic lesion. Variable rates of progression have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study of 85 patients with atherosclerotic renal artery stenosis who underwent serial angiograms found that stenotic lesions progressed in 37 patients at four years (44 percent) and occluded in 14 patients (16 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study identified 1189 patients with various degrees of renal artery stenosis who had repeated renal arteriograms separated by an average of 2.6 years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/19\">",
"       19",
"      </a>",
"      ]. Progression of stenosis occurred in 11 percent of patients and did not depend upon the baseline severity of stenosis.",
"     </li>",
"     <li>",
"      A third study of 170 patients who underwent serial duplex ultrasonography found that the rate of progression of stenosis was 35 percent at three years and 52 percent at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/20\">",
"       20",
"      </a>",
"      ]. Progression was more likely to occur in patients who had more severe stenoses at baseline: the three-year incidence of progression was 49 percent if the baseline stenosis was 60 percent or greater and 28 percent if the baseline stenosis was less than 60 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progression to end-stage renal failure (ESRD) is rare in patients with unilateral disease. Among over 300 patients with atherosclerotic renal artery stenosis, for example, progression to ESRD over a 4- to 10-year period occurred in only one patient, even though some patients had an initial stenotic lesion of 70 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/5,21\">",
"     5,21",
"    </a>",
"    ]. No mention was made concerning radiographic progression of these lesions or the incidence and complications of hypertension.",
"   </p>",
"   <p>",
"    Although ESRD is uncommon in these patients, progressive renal disease of lesser severity commonly occurs. In two randomized trials, progression of renal disease (defined as a fall in glomerular filtration rate [GFR by 20 percent or a doubling of serum creatinine) in patients assigned to medical therapy developed in 16 to 22 percent at two to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progression is more likely in patients with bilateral renal artery stenosis or stenosis of a solitary functioning kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with atherosclerotic renovascular disease have an increased rate of extrarenal atherosclerosis and as much as a two- to fourfold increase for cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issues of progression of atherosclerotic renal artery stenosis and increased cardiovascular risk are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Progression of renal artery lesions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\", section on 'Association with systemic atherosclerosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with FMD, the likelihood of progression is lower, total occlusion is rare, and there is no association with systemic atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations and diagnosis of fibromuscular dysplasia\", section on 'Monitoring disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Impaired renal function with angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high angiotensin II levels induced by reduced renal blood flow act to preserve the GFR by preferentially increasing the resistance at the efferent (postcapillary) glomerular arteriole. Inhibiting this compensatory response with an ACE inhibitor or ARB can lower GFR in the ischemic kidney, even though the associated decrease in renal vascular resistance may preserve renal blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. A more complete discussion of the role of angiotensin II in the regulation of GFR in renovascular hypertension is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"     \"Renal effects of ACE inhibitors in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in humans with unilateral renal artery stenosis demonstrate that, despite the reduction in filtration in the stenotic kidney, the total GFR is usually well maintained due to a roughly equivalent rise in filtration in the contralateral kidney following the removal of angiotensin II-induced vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/26\">",
"     26",
"    </a>",
"    ]. A modest elevation in the serum creatinine concentration can occur in selected cases, a change that may be due to intrarenal vascular disease (nephrosclerosis) in the contralateral kidney that has been exposed to high systemic pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]. A more significant reduction in renal function has been described in elderly patients with a baseline GFR less than 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decline in GFR is less common with other antihypertensive agents, which do not preferentially decrease the resistance at the efferent arteriole. However, when vascular stenosis reaches a \"critical\" level, reduction in perfusion pressure with any antihypertensive agent can lower GFR, which will be clinically evident in patients who have bilateral disease (",
"    <a class=\"graphic graphic_figure graphicRef75208 \" href=\"UTD.htm?25/35/26173\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Loss of functional renal mass in the stenotic kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional concern when medical therapy alone is used to treat unilateral atherosclerotic renal artery stenosis is the long-term effect of reduced blood flow and perfusion pressures on the stenotic kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/30\">",
"     30",
"    </a>",
"    ]. The kidney receives an abundant blood supply in its role as a filtering organ and can adapt to moderately reduced blood flow without developing overt tissue ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/31\">",
"     31",
"    </a>",
"    ]. Nonetheless, sufficient reduction of blood flow eventually produces cortical hypoxia, microvascular rarefaction, and development of interstitial inflammation, tubular atrophy, and irreversible fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that these changes are more likely to occur with angiotensin inhibition [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/25\">",
"     25",
"    </a>",
"    ], but this finding has not been uniform.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated 122 patients with unilateral or bilateral disease in whom duplex ultrasonography was performed every six months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/35\">",
"       35",
"      </a>",
"      ]. An enhanced risk of loss of mass in the ischemic kidney was associated with a greater degree of stenosis and a higher blood pressure (systolic pressure greater than 180 mmHg) but",
"      <strong>",
"       not",
"      </strong>",
"      with the use of ACE inhibitors. At two years, the incidence of kidney atrophy, defined as a reduction in kidney length of greater than 1 cm, was 5.5, 11.7, and 20.8 percent in those with a baseline renal artery disease categorized as normal, less than 60 percent stenosis, and greater than 60 percent stenosis, respectively (p = 0.009).",
"     </li>",
"     <li>",
"      A second report performed serial duplex Doppler ultrasonographic studies in 54 patients with at least a 60 percent stenosis in at least one renal artery to assess both the degree of renal artery stenosis and kidney size [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/36\">",
"       36",
"      </a>",
"      ]. The type of therapy was not described. At one year, more than a 1.0 cm decrease in kidney size occurred in 13 percent of patients with unilateral disease versus 43 percent with bilateral stenoses. Cumulative progression to total occlusion was 2.1 percent at one year and 5 percent at two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, persistent severe stenosis appears to carry the risk of long-term loss of renal mass. The functional consequences are greater in patients with bilateral disease in whom progressive kidney failure can occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=see_link\">",
"     \"Chronic kidney disease associated with atherosclerotic renovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Percutaneous transluminal renal angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transluminal renal angioplasty (PTRA) provides a nonsurgical method to open stenotic renal arteries (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71793 graphicRef67188 \" href=\"UTD.htm?30/35/31283\">",
"     image 1A-B",
"    </a>",
"    ). Based upon various studies, the major conclusions regarding PTRA include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The maximum antihypertensive response is generally observed at 48 hours after the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/37\">",
"       37",
"      </a>",
"      ]. Blood pressure levels and antihypertensive drug requirements often change over subsequent weeks. A final determination of the blood pressure response to PTRA should not be made during this interval.",
"     </li>",
"     <li>",
"      The technical success rate varies with the site of the lesion. In general, the most amenable lesions to angioplasty are those producing incomplete occlusion in the main renal artery. Total occlusions and ostial lesions (which also involve the aorta) generally do not respond well to angioplasty alone due to elastic recoil. Most atherosclerotic lesions are now treated with primary stenting to avoid rapid development of restenosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Stent placement'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Among patients with unilateral atherosclerotic disease, PTRA alone results in normalization of blood pressure (ie, removal of antihypertensive drug therapy) in 8 to 20 percent, improvement in 50 to 60 percent, a failure rate of approximately 20 to 30 percent, and a restenosis rate of 8 to 30 percent at two years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Results were somewhat better with unilateral fibromuscular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/40\">",
"       40",
"      </a>",
"      ]. The results are less consistent for patients with bilateral disease or chronic hypertension compared with patients who have an acute elevation in blood pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Stent placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients undergoing PTRA for treatment of atherosclerotic renal artery stenosis, we suggest stent placement. In a randomized trial, PTRA alone was compared with PTRA plus stent placement in 85 hypertensive patients with ostial atherosclerotic renal artery stenosis (51 percent of which were unilateral); all patients were hypertensive",
"    <span class=\"nowrap\">",
"     (&gt;160/95",
"    </span>",
"    mmHg, mean",
"    <span class=\"nowrap\">",
"     186/103",
"    </span>",
"    mmHg), the mean degree of stenosis was 76 percent, and the mean serum creatinine was 1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (139",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/41\">",
"     41",
"    </a>",
"    ]. The patients were randomly assigned to one or the other intervention.",
"   </p>",
"   <p>",
"    PTRA plus stenting was associated with the following significant benefits compared with PTRA alone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher initial primary success rate, defined as less than 50 percent stenosis (88 versus 57 percent)",
"     </li>",
"     <li>",
"      At six months, a higher patency rate (75 versus 29 percent) and a lower restenosis rate (14 versus 48 percent)",
"     </li>",
"     <li>",
"      Twelve patients assigned to PTRA alone underwent stenting because of treatment failure within six months. These patients had a similar blood pressure response as those initially treated with stenting.",
"     </li>",
"     <li>",
"      The rate of normalization or improvement in blood pressure control was not significantly higher in the stenting group on intention to treat analysis (58 versus 49 percent), but this finding was influenced by the inclusion of 12 patients originally assigned to PTRA who underwent secondary stenting.",
"     </li>",
"     <li>",
"      Most patients had stable renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a number of prospective studies indicate that PTRA with stent placement compared with PTRA alone decreases the rate of restenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/39,41-44\">",
"     39,41-44",
"    </a>",
"    ] and is more effective in terms of improving blood pressure and stabilizing or improving renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/39,42-46\">",
"     39,42-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our suggestion that a stent be placed in patients undergoing PTRA for treatment of atherosclerotic renal artery stenosis is consistent with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/6\">",
"     6",
"    </a>",
"    ]. PTRA without stent placement is rarely performed unless the anatomy precludes stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Procedural complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of procedural complications can occur with angioplasty with or without stenting. Most are relatively minor and include puncture site hematoma and renal artery dissection. However, serious problems can arise, including renal artery thrombosis or perforation (often requiring surgery) and acute kidney injury due to atheroembolic disease (which may be irreversible) or to a reaction to the radiocontrast agent (which is usually reversible). These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\", section on 'Procedural complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Restenosis rates range between 11 and 17 percent and may be detected as a rise in blood pressure requiring more intensive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Split kidney function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since total GFR is usually well maintained in patients with unilateral renal artery stenosis, another measure of success after PTRA may be the relative loss of lateralization of kidney function. In a prospective study, 32 hypertensive patients with unilateral renal artery stenosis (&ge;60 percent stenosis on angiography) and normal global kidney function underwent PTRA, with follow-up in part consisting of split kidney function assessment, including single kidney and global GFR measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/48\">",
"     48",
"    </a>",
"    ]. At six months postprocedure, the GFR significantly increased in the stenotic kidneys (31 to 41",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) and fell in the nonstenotic kidneys (59 to 53",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2). It is unclear whether these findings are associated with long-term renal benefits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical renal revascularization has been performed less commonly since the widespread application of effective antihypertensive drug therapy and endovascular stents in the mid-1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/49\">",
"     49",
"    </a>",
"    ]. We agree with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines that, among patients who have an indication for renal artery revascularization, surgery is only preferred for selected patients who have complex anatomic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple small renal arteries",
"     </li>",
"     <li>",
"      Early primary branching of the main renal artery",
"     </li>",
"     <li>",
"      Requirement for aortic reconstruction near the renal arteries for other indications, such as aneurysm repair or severe aortoiliac occlusive disease",
"     </li>",
"     <li>",
"      In order to avoid manipulation of a highly diseased aorta or failed endovascular stents (using specific surgical techniques, including splenorenal, ileorenal, or hepatorenal bypass procedures)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical therapy in unilateral atherosclerotic renal artery stenosis consists of bypassing the stenotic segment or of removing a small atrophic kidney with nearly complete arterial occlusion. Surgery is equally or more effective than PTRA in the treatment of atherosclerotic disease, with cure of or improvement in the hypertension occurring in 80 to 95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/52\">",
"     52",
"    </a>",
"    ]. Cure of hypertension after surgery is most likely in patients who have been hypertensive for less than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/53\">",
"     53",
"    </a>",
"    ]. In this study, a lack of complete response was usually associated with one of two factors: the presence of underlying essential hypertension, upon which renovascular disease has been superimposed, or the development of intrarenal vascular disease due to exposure of the contralateral kidney to the elevated blood pressure.",
"   </p>",
"   <p>",
"    In a randomized trial, 58 patients with unilateral atherosclerotic renal artery stenosis were assigned to surgery or PTRA without stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/54\">",
"     54",
"    </a>",
"    ]. Surgery was associated with a higher primary success rate (97 versus 83 percent) and a lower incidence of restenosis at two years (4 versus 25 percent). However, the outcomes were similar in the two groups since almost all patients with restenosis could be successfully treated with repeat PTRA.",
"   </p>",
"   <p>",
"    The mortality rate associated with surgery for atherosclerotic renal artery stenosis varies with the severity of the extrarenal vascular disease, the degree of surgery required, and the experience of the local surgical team. Overall mortality rates below 2.5 percent have been reported from some of the most experienced centers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/52,55,56\">",
"     52,55,56",
"    </a>",
"    ]. The outcome is best in younger patients (less than 65 years old) who do not have symptomatic coronary or cerebrovascular disease and who require only renal artery surgery. Most operative deaths occur in patients with diffuse atherosclerosis who also have heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    moderate to advanced chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29369/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=see_link\">",
"       \"Patient information: Renovascular hypertension (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases of renal artery stenosis, one kidney is affected with the second kidney being essentially normal, hence the designation, \"unilateral\" disease. Individuals with high-grade stenosis to both kidneys, or to a solitary functioning kidney thereby affecting the entire functioning renal mass, are considered to have \"bilateral\" disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two major causes of unilateral renal artery stenosis (see",
"      <a class=\"local\" href=\"#H5462401\">",
"       'Etiology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Atherosclerosis, which primarily affects patients (particularly men) over the age of 45 years and usually involves the aortic orifice or the proximal main renal artery. This disorder is particularly common in patients with diffuse atherosclerosis.",
"     </li>",
"     <li>",
"      Fibromuscular dysplasia (FMD), which most often affects women under the age of 50 years and typically involves the distal main renal artery or the intrarenal branches. Fibromuscular disease is discussed in other topics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=see_link\">",
"       \"Clinical manifestations and diagnosis of fibromuscular dysplasia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=see_link\">",
"       \"Treatment of fibromuscular dysplasia of the renal arteries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a number of clinical findings that suggest an increased likelihood of secondary hypertension, some of which specifically suggest the presence of renovascular disease (",
"      <a class=\"graphic graphic_table graphicRef56130 \" href=\"UTD.htm?41/38/42604\">",
"       table 1",
"      </a>",
"      ). These clinical clues, the indications for testing to establish the diagnosis of renal artery stenosis, and the imaging studies used to establish the diagnosis are presented in detail in other topics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link\">",
"       \"Who should be evaluated for renovascular or other causes of secondary hypertension?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H517662#H517662\">",
"       \"Establishing the diagnosis of renovascular hypertension\", section on 'Indications for testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=see_link&amp;anchor=H16699485#H16699485\">",
"       \"Establishing the diagnosis of renovascular hypertension\", section on 'Diagnostic test options'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Patients with atherosclerotic renovascular disease have a high rate of systemic atherosclerosis and are at increased risk for adverse cardiovascular outcomes. As a result, they are considered to have a coronary artery disease equivalent and should be treated according to current guidelines for secondary prevention of cardiovascular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with unilateral renal artery stenosis who are hypertensive should receive antihypertensive therapy. The data and specific recommendations are presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are effective in patients with renovascular disease; additional medications are frequently required. Potential concerns with the use of medical therapy without revascularization include progression of the stenosis, impaired kidney function with angiotensin inhibition, and long-term ischemic damage of the stenotic kidney. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with unilateral renal artery stenosis who meet one or more of the following four criteria, we suggest revascularization rather than medical therapy alone; revascularization is usually achieved by percutaneous angioplasty with stenting (or surgical revascularization in patients with complex anatomic lesions) (see",
"      <a class=\"local\" href=\"#H5462771\">",
"       'Revascularization versus medical therapy alone'",
"      </a>",
"      above) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A short duration of blood pressure elevation prior to the diagnosis of renovascular disease, since this is the strongest clinical predictor of a fall in blood pressure after renal revascularization",
"     </li>",
"     <li>",
"      Failure of optimal medical therapy to control the blood pressure",
"     </li>",
"     <li>",
"      Intolerance to optimal medical therapy",
"     </li>",
"     <li>",
"      Recurrent flash pulmonary edema",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      refractory heart failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with unilateral renal artery stenosis who do not meet one of the four criteria just listed, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      revascularizing and instead treating with medical therapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5462771\">",
"       'Revascularization versus medical therapy alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients undergoing percutaneous transluminal renal angioplasty (PTRA) for treatment of atherosclerotic renal artery stenosis, we suggest stent placement unless the anatomy precludes stenting (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Percutaneous transluminal renal angioplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients who have an indication for renal artery revascularization, surgery is only preferred for selected patients who have complex anatomic lesions (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Surgery'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Multiple small renal arteries",
"     </li>",
"     <li>",
"      Early primary branching of the main renal artery",
"     </li>",
"     <li>",
"      Requirement for aortic reconstruction near the renal arteries for other indications, such as aneurysm repair or severe aortoiliac occlusive disease",
"     </li>",
"     <li>",
"      In order to avoid manipulation of a highly diseased aorta or failed endovascular stents (using specific surgical techniques, including splenorenal, ileorenal, or hepatorenal bypass procedures)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/1\">",
"      Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med 2001; 344:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/2\">",
"      ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/3\">",
"      Bax L, Woittiez AJ, Kouwenberg HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med 2009; 150:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/4\">",
"      Olin JW, Melia M, Young JR, et al. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990; 88:46N.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/5\">",
"      Leertouwer TC, Pattynama PM, van den Berg-Huysmans A. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? Kidney Int 2001; 59:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/6\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/7\">",
"      Marcantoni C, Zanoli L, Rastelli S, et al. Effect of renal artery stenting on left ventricular mass: a randomized clinical trial. Am J Kidney Dis 2012; 60:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/8\">",
"      Kumbhani DJ, Bavry AA, Harvey JE, et al. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J 2011; 161:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/9\">",
"      van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000; 342:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/10\">",
"      Plouin PF, Chatellier G, Darn&eacute; B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998; 31:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/11\">",
"      Webster J, Marshall F, Abdalla M, et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998; 12:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/12\">",
"      Mann SJ, Sos TA. Misleading results of randomized trials: the example of renal artery stenting. J Clin Hypertens (Greenwich) 2010; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/13\">",
"      White CJ. The need for randomized trials to prove the safety and efficacy of parachutes, bulletproof vests, and percutaneous renal intervention. Mayo Clin Proc 2011; 86:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/14\">",
"      Kalra PA, Chrysochou C, Green D, et al. The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease. Catheter Cardiovasc Interv 2010; 75:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/15\">",
"      Gray BH, Olin JW, Childs MB, et al. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med 2002; 7:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/16\">",
"      Tullis MJ, Caps MT, Zierler RE, et al. Blood pressure, antihypertensive medication, and atherosclerotic renal artery stenosis. Am J Kidney Dis 1999; 33:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/17\">",
"      Dworkin LD, Cooper CJ. Clinical practice. Renal-artery stenosis. N Engl J Med 2009; 361:1972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/18\">",
"      Pohl MA, Novick AC. Natural history of atherosclerotic and fibrous renal artery disease: clinical implications. Am J Kidney Dis 1985; 5:A120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/19\">",
"      Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. Am Heart J 1998; 136:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/20\">",
"      Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. Circulation 1998; 98:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/21\">",
"      Conlon PJ, O'Riordan E, Kalra PA. New insights into the epidemiologic and clinical manifestations of atherosclerotic renovascular disease. Am J Kidney Dis 2000; 35:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/22\">",
"      Ch&aacute;bov&aacute; V, Schirger A, Stanson AW, et al. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc 2000; 75:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/23\">",
"      Kalra PA, Guo H, Kausz AT, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int 2005; 68:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/24\">",
"      Schoolwerth AC, Sica DA, Ballermann BJ, et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/25\">",
"      Hricik DE, Dunn MJ. Angiotensin-converting enzyme inhibitor-induced renal failure: causes, consequences, and diagnostic uses. J Am Soc Nephrol 1990; 1:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/26\">",
"      Hollenberg NK. The treatment of renovascular hypertension: surgery, angioplasty, and medical therapy with converting-enzyme inhibitors. Am J Kidney Dis 1987; 10:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/27\">",
"      Franklin SS, Smith RD. Comparison of effects of enalapril plus hydrochlorothiazide versus standard triple therapy on renal function in renovascular hypertension. Am J Med 1985; 79:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/28\">",
"      Onuigbo MA, Onuigbo NT. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. QJM 2008; 101:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/29\">",
"      Textor SC, Novick AC, Tarazi RC, et al. Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease. Ann Intern Med 1985; 102:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/30\">",
"      Jackson B, McGrath BP, Matthews PG, et al. Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension 1986; 8:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/31\">",
"      Gloviczki ML, Glockner JF, Lerman LO, et al. Preserved oxygenation despite reduced blood flow in poststenotic kidneys in human atherosclerotic renal artery stenosis. Hypertension 2010; 55:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/32\">",
"      V&eacute;niant M, Heudes D, Clozel JP, et al. Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int 1994; 46:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/33\">",
"      Keddis MT, Garovic VD, Bailey KR, et al. Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant 2010; 25:3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/34\">",
"      Gloviczki ML, Glockner JF, Crane JA, et al. Blood oxygen level-dependent magnetic resonance imaging identifies cortical hypoxia in severe renovascular disease. Hypertension 2011; 58:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/35\">",
"      Caps MT, Zierler RE, Polissar NL, et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int 1998; 53:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/36\">",
"      Strandness DE Jr. Natural history of renal artery stenosis. Am J Kidney Dis 1994; 24:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/37\">",
"      Bonelli FS, McKusick MA, Textor SC, et al. Renal artery angioplasty: technical results and clinical outcome in 320 patients. Mayo Clin Proc 1995; 70:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/38\">",
"      Beck AW, Nolan BW, De Martino R, et al. Predicting blood pressure response after renal artery stenting. J Vasc Surg 2010; 51:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/39\">",
"      Tuttle KR, Chouinard RF, Webber JT, et al. Treatment of atherosclerotic ostial renal artery stenosis with the intravascular stent. Am J Kidney Dis 1998; 32:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/40\">",
"      Trinquart L, Mounier-Vehier C, Sapoval M, et al. Efficacy of revascularization for renal artery stenosis caused by fibromuscular dysplasia: a systematic review and meta-analysis. Hypertension 2010; 56:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/41\">",
"      van de Ven PJ, Kaatee R, Beutler JJ, et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomised trial. Lancet 1999; 353:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/42\">",
"      Blum U, Krumme B, Fl&uuml;gel P, et al. Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty. N Engl J Med 1997; 336:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/43\">",
"      Rocha-Singh K, Jaff MR, Rosenfield K, ASPIRE-2 Trial Investigators. Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study. J Am Coll Cardiol 2005; 46:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/44\">",
"      van de Ven PJ, Beutler JJ, Kaatee R, et al. Transluminal vascular stent for ostial atherosclerotic renal artery stenosis. Lancet 1995; 346:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/45\">",
"      Rees CR, Palmaz JC, Becker GJ, et al. Palmaz stent in atherosclerotic stenoses involving the ostia of the renal arteries: preliminary report of a multicenter study. Radiology 1991; 181:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/46\">",
"      Zeller T, Frank U, M&uuml;ller C, et al. Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. Circulation 2003; 108:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/47\">",
"      Henry M, Amor M, Henry I, et al. Stents in the treatment of renal artery stenosis: long-term follow-up. J Endovasc Surg 1999; 6:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/48\">",
"      La Batide-Alanore A, Azizi M, Froissart M, et al. Split renal function outcome after renal angioplasty in patients with unilateral renal artery stenosis. J Am Soc Nephrol 2001; 12:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/49\">",
"      Murphy TP, Soares G, Kim M. Increase in utilization of percutaneous renal artery interventions by medicare beneficiaries, 1996-2000. AJR Am J Roentgenol 2004; 183:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/50\">",
"      Stanley JC. David M. Hume memorial lecture. Surgical treatment of renovascular hypertension. Am J Surg 1997; 174:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/51\">",
"      Novick AC. Long-term results of surgical revascularization for renal artery disease. Urol Clin North Am 2001; 28:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/52\">",
"      Lawrie GM, Morris GC Jr, Glaeser DH, DeBakey ME. Renovascular reconstruction: factors affecting long-term prognosis in 919 patients followed up to 31 years. Am J Cardiol 1989; 63:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/53\">",
"      Hughes JS, Dove HG, Gifford RW Jr, Feinstein AR. Duration of blood pressure elevation in accurately predicting surgical cure of renovascular hypertension. Am Heart J 1981; 101:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/54\">",
"      Weibull H, Bergqvist D, Bergentz SE, et al. Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study. J Vasc Surg 1993; 18:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/55\">",
"      Hansen KJ, Starr SM, Sands RE, et al. Contemporary surgical management of renovascular disease. J Vasc Surg 1992; 16:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29369/abstract/56\">",
"      Novick AC. Current concepts in the management of renovascular hypertension and ischemic renal failure. Am J Kidney Dis 1989; 13:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3834 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29369=[""].join("\n");
var outline_f28_43_29369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5462347\">",
"      BRIEF REVIEW OF PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5462354\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5462401\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Clinical clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTOR REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5462582\">",
"      General approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5462771\">",
"      Revascularization versus medical therapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5463575\">",
"      Overview of therapeutic options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Progression of stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Impaired renal function with angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Loss of functional renal mass in the stenotic kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Percutaneous transluminal renal angioplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stent placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Procedural complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Split kidney function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3834|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/14/21743\" title=\"diagnostic image 1A\">",
"      Arteriogram in RA stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/19/1328\" title=\"diagnostic image 1B\">",
"      Angioplasty in RA stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3834|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/35/26173\" title=\"figure 1\">",
"      Nitroprusside in RA stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3834|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/38/42604\" title=\"table 1\">",
"      Features of secondary HTN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33433?source=related_link\">",
"      Chronic kidney disease associated with atherosclerotic renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34471?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromuscular dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/31001?source=related_link\">",
"      Establishing the diagnosis of renovascular hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/20/37186?source=related_link\">",
"      Patient information: Renovascular hypertension (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26631?source=related_link\">",
"      Treatment of fibromuscular dysplasia of the renal arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_43_29370="Risk factors for and possible causes of osteoarthritis";
var content_f28_43_29370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors for and possible causes of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29370/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29370/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29370/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/43/29370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/43/29370/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/43/29370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis was previously thought to be a normal consequence of aging, thereby leading to the term degenerative joint disease. However, it is now realized that osteoarthritis results from a complex interplay of multiple factors, including joint integrity, genetics, local inflammation, mechanical forces, and cellular and biochemical processes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/1\">",
"     1",
"    </a>",
"    ]. A discussion of how these factors interact to cause cartilage loss and related bony changes is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=see_link\">",
"     \"Pathogenesis of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, inherited conditions may predispose individuals to develop osteoarthritis. For the majority of patients, osteoarthritis is linked to one or more factors, such as aging, occupation, trauma, and repetitive, small insults over time. These associations are strongest for osteoarthritis of the knee and hand and are less strong for the hip. How these factors interact with genetics and other factors in the development of osteoarthritis remains unclear.",
"   </p>",
"   <p>",
"    The risk factors for and possible causes of osteoarthritis will be reviewed here. Clinical manifestations, classification, and diagnosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of osteoarthritis, including nonpharmacologic approaches, pharmacologic treatment, and surgical therapies, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND POSSIBLE CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple risk factors have been linked to osteoarthritis in epidemiology studies including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Female versus male sex",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Lack of osteoporosis",
"     </li>",
"     <li>",
"      Occupation",
"     </li>",
"     <li>",
"      Sports activities",
"     </li>",
"     <li>",
"      Previous injury",
"     </li>",
"     <li>",
"      Muscle weakness",
"     </li>",
"     <li>",
"      Proprioceptive deficits",
"     </li>",
"     <li>",
"      Genetic elements",
"     </li>",
"     <li>",
"      Acromegaly",
"     </li>",
"     <li>",
"      Calcium crystal deposition disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced age is one of the strongest risk factors associated with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. The National Health and Nutrition Examination Survey found the prevalence of this disease to be less than 0.1 percent in those aged 25 to 34 years old versus a rate of over 80 percent in people over age 55 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. These findings are consistent with those of early studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1958, a study found osteoarthritis in 83 and 87 percent of males and females aged 55 to 64 years old, respectively.",
"     </li>",
"     <li>",
"      In 1973, age related increases in osteoarthritis were reported in both men (incident osteoarthritis of 9.4 percent in those aged 15 to 24 versus 97 percent in those over age 65) and women (incident osteoarthritis of 7.6 percent in those aged 15 to 24 versus 97 percent in patients at age 65 and over) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FEMALE SEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Innumerable studies have found that female sex is associated with an increased risk of osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. The relative risk of developing osteoarthritis for women has been estimated to be 2.6 after adjustment for age, weight, and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/8\">",
"     8",
"    </a>",
"    ]. Women with OA are also more likely than men to experience rapid structural damage and to undergo total hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/9\">",
"     9",
"    </a>",
"    ]. The reason for these increased risks in women remains unclear, but it may be related to hormones, genetics, or other undetermined factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=see_link\">",
"     \"Pathogenesis of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OBESITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is perhaps the strongest modifiable risk factor for the development of osteoarthritis. Although multiple studies have demonstrated a relationship between obesity and osteoarthritis, newer studies better define this association and its implications on the prevention of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/3-6,8,10-18\">",
"     3-6,8,10-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the association of obesity as a risk factor for osteoarthritis varies by joint, the following review will be conducted according to the principle affected anatomic areas in osteoarthritis: the knees, hands, and hips.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Knee",
"    </span>",
"    &nbsp;&mdash;&nbsp;Utilizing data from the Chingford study, two studies have quantified a strong association between obesity and osteoarthritis of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/13,19\">",
"     13,19",
"    </a>",
"    ]. In these studies, height, weight, waist, and the circumference of the hips and mid-thigh were measured, and subjects were divided into tertiles based on body mass index. Women of age 45 to 64 were considered to have osteoarthritis if their Kellgren and Lawrence score was two or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/13,19\">",
"     13,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with the lowest obesity tertile, patients in the highest tertile in one of the studies had an odds ratio of 6.17 for radiographic osteoarthritis and 8.57 for radiographic and symptomatic osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/13\">",
"     13",
"    </a>",
"    ]. For every two unit increase in body mass index (equivalent to approximately 5 kg), the odds ratio for radiographic knee osteoarthritis increased by 1.36. The distribution of fat, however, was not found to be significant. Limitations of the study include its cross sectional nature and the predominance of Caucasians.",
"   </p>",
"   <p>",
"    A follow-up, longitudinal study of this patient population evaluated the risk for the development of contralateral knee osteoarthritis in middle aged women with established unilateral disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/14\">",
"     14",
"    </a>",
"    ]. This Chingford population again consisted of predominantly Caucasian, middle class females, and, as in the previous study, patients with unilateral knee osteoarthritis of grade 2 or above by the Kellgren and Lawrence scale were included. Of the 67 women with unilateral disease, 20 (34 percent) developed contralateral disease by radiographic criteria at 24 months. Among those with incident osteoarthritis, only 10 percent of patients with low body mass index (BMI) tertile developed osteoarthritis versus 25 and 47 percent in the middle and highest tertile, respectively. The relative risk was 4.69 from the lowest to highest obesity tertile. Furthermore, the risk of contralateral osteoarthritis increased by 6.5 percent for each additional 5 kilogram of weight. Female patients with unilateral osteoarthritis are, therefore, at high risk of developing contralateral disease, and an enhanced risk is associated with increasing weight.",
"   </p>",
"   <p>",
"    Among older adults, the combination of obesity and heavy physical activity is associated with an enhanced risk of osteoarthritis of the knee, defined radiologically. Using data from the Framingham heart study (the Framingham Osteoarthritis Study), older individuals (average age of 70 years) in the upper tertile of BMI who performed at least three hours per day of significant physical activity had an odds ratio of 13 of developing knee osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/20\">",
"     20",
"    </a>",
"    ]. Lesser degrees of activity were not associated with an enhanced risk. In another, younger cohort of Framingham residents (mean age 53 years) followed for nine years, the incidence of symptomatic or radiographic OA of the knee was not significantly different in those with lower versus higher levels of self-reported physical activity regardless of initial weight or BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of symptomatic osteoarthritis of the knee among patients with radiographic osteoarthritis in the Framingham Osteoarthritis Study cohort increased over the 20 years between 1983 to 1985 and 2002 to 2005, after adjustment for both age and body mass index (from 26 to 49 percent in women and from 19 to 49 percent in men) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/22\">",
"     22",
"    </a>",
"    ]. Knee pain and obesity also increased in the same interval in this cohort and in national survey data in the US. However, increased obesity only explained a portion of the change (about 10 to 25 percent), and, notably, radiographic knee osteoarthritis did not increase during this interval. The precise factors responsible for these increases in symptom prevalence and an increased rate of knee joint replacement surgery during this period are uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hand",
"    </span>",
"    &nbsp;&mdash;&nbsp;Utilizing data from the Tecumseh Community Health Study, one study prospectively evaluated the risks for developing osteoarthritis of the hand. Patients with pre-existing osteoarthritis or rheumatoid arthritis were excluded. A weight index was calculated utilizing sex-specific desired weight to height ratios from Metropolitan Life actuarial tables; obesity was defined as an index of greater than 120 percent. Over the 23 year period, there was a 41 percent incidence of hand osteoarthritis as defined by radiographic criteria in the Atlas of Standard Radiographs of Arthritis. Obesity was associated with a relative risk of 3.12 for the development of hand osteoarthritis. This enhanced rate occurred in obese patients without pre-existing disease, thereby supporting the hypothesis that obesity is causal in osteoarthritis. The findings of this study support the postulate that decreased exercise resulting from joint pain is not the only reason why obesity is associated with osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although obesity may cause osteoarthritis of the knees and hands, less consistent data support a relationship between hip osteoarthritis and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/4,7,15-17\">",
"     4,7,15-17",
"    </a>",
"    ]. One study of Finnish patients age 30 and over selected from a population registry found hip osteoarthritis (as defined by clinical and radiographic criteria) in 6 and 4 percent of women and men, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/4\">",
"     4",
"    </a>",
"    ]. The incidence of arthritis increased with increased body mass index, with an enhanced odds ratio of 2.8 for bilateral hip disease from the lowest and highest weight groups. However, this report was flawed in part because of a cross-sectional design. Nevertheless, in an all-women study, a significant correlation with obesity was seen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/23\">",
"     23",
"    </a>",
"    ]. A significant association between BMI and total hip arthroplasty for OA was also noted in a cohort of over one million Norwegian men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, another study of over 1000 male medical students found that increased body mass index measured at ages 20 to 39 years enhanced the risk of developing knee, but not hip, osteoarthritis at follow-up at 36 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Risk reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of osteoarthritis associated with obesity may be modifiable. As an example, one report of 64 patients with osteoarthritis of recent onset from the Framingham knee osteoarthritis study found a correlation between weight change and osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/5\">",
"     5",
"    </a>",
"    ]. Most cases of osteoarthritis occurred in women who had gained at least four units of body mass index or in those with gains of between two and four BMI units. The lowest rate of incident disease occurred in women who lost two to four BMI units. By examining the rate over time, any increase in BMI was correlated with a nonsignificant trend toward higher risk for symptomatic osteoarthritis, and a loss in BMI was significantly correlated with a decreased risk. Unfortunately, the findings of the study are weakened by its reliance upon the recall of the date of symptom onset.",
"   </p>",
"   <p>",
"    Since obesity is the most modifiable risk factor associated with the development of osteoarthritis, clinicians should counsel their patients that weight loss will decrease their risk. It is likely that even modest weight loss will provide some benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Associated disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis due to obesity is also associated with significant morbidity. One study, for example, examined the relationships between obesity, osteoarthritis, and disability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/3\">",
"     3",
"    </a>",
"    ]. Using a patient population in a rural southeastern section of the United States which included a significant proportion of African-Americans, the study sought independent risk factors for disability from osteoarthritis. Variables included age, race, sex, level of education, marital status, knee pain on most days, severity of knee pain, the Health Assessment Questionnaire (HAQ), body mass index, and knee radiographs. Only age (particularly age greater than 75), female sex, obesity, and knee pain severity had independent impacts on mean HAQ scores. Specifically, obesity was significantly associated with a worse HAQ score and more severe knee pain. This study is important in both its examination of the functional status of its cohort and its inclusion of a significant number of African-American patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LACK OF OSTEOPOROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher bone mass is associated with an increased risk of hip osteoarthritis in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. As an example, the radiographs of 4855 women aged 65 and older were examined for radiographic evidence of osteoarthritis and compared with measurements of bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/28\">",
"     28",
"    </a>",
"    ]. Women with moderate to severe evidence of osteoarthritis had higher bone mineral density measurements than those without osteoarthritis. This inverse association between osteoporosis and osteoarthritis was supported by a large cross-sectional study which controlled for the effects of estrogen replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar relation exists between bone mineral density and the prevalence of osteoarthritis of the knee. In the Framingham study population, the prevalence of radiographic osteoarthritis was 17 percent in 115 women in the lowest quartile of bone mineral density and increased steadily to 34 percent for those in the highest quartile of bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/30\">",
"     30",
"    </a>",
"    ]. Despite the positive association between bone density and radiographic prevalence of osteoarthritis, the same study found that women who were more osteopenic were more likely to have progressive worsening of their osteoarthritis, at least radiographically, than those with higher bone density.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Estrogen replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevention of bone loss via estrogen replacement therapy (ERT) should, therefore, enhance the development of osteoarthritis. Support for this hypothesis is provided by the results of some animal models of osteoarthritis in which the administration of estrogen promoted cartilage damage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. This result, however, was not found in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinical studies suggest that postmenopausal ERT protects women from developing large joint osteoarthritis (thereby resulting in a lower than expected risk of knee and hip osteoarthritis), while others show only a neutral effect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Of these studies, four evaluated the effect of ERT on prevalent disease, and one studied the effect on incident and progressive radiographic disease. A meta-analysis of the four prevalence studies suggested an inverse relationship. This association was supported by another study which reported a strong inverse relationship between ERT and osteoarthritis among women receiving long term ERT for both prevalent radiographic osteoarthritis and incident osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, one case-control study failed to confirm the finding that ERT protects women from developing osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/39\">",
"     39",
"    </a>",
"    ]. Although there was a modest but nonsignificant inverse association between past use and the development of osteoarthritis, ongoing use was not associated with osteoarthritis risk. Likewise, in a four year prospective study of ERT in women (HERS trial) that randomly assigned subjects to",
"    <span class=\"nowrap\">",
"     estrogen/progestin",
"    </span>",
"    or placebo, there was no significant difference in the prevalence of knee pain or in the degree of disability between those on ERT or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the evidence from studies is conflicting, there may be many potential co-variables that may not have been adequately controlled. Although a randomized, prospective clinical trial might help to clarify the effect of ERT on the development of osteoarthritis, such a trial seems unlikely to be performed given current concern about the risks of such therapy in postmenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OCCUPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of occupation and osteoarthritis has been examined in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/1-11\">",
"     1-11",
"    </a>",
"    ], and reports have linked knee osteoarthritis with specific occupations, including cotton workers, dock workers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/12\">",
"     12",
"    </a>",
"    ], shipyard workers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/9\">",
"     9",
"    </a>",
"    ], and carpenters [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/13\">",
"     13",
"    </a>",
"    ]. Hand and hip osteoarthritis have also all been evaluated and linked to occupations associated with physical labor. Despite these associations, it is unclear whether a change in occupation lessens the risk of osteoarthritis.",
"   </p>",
"   <p>",
"    Mechanisms for the association between occupation and osteoarthritis remain unclear but may involve joint loading and repetitive damage over time. Since these processes likely differ from joint area to joint area, occupational osteoarthritis will be examined separately by affected joint area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Knee",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain occupational activities, especially those related to repetitive knee bending, appear to be risk factors for the development of knee osteoarthritis. As an example, a case-control study of patients with symptomatic knee osteoarthritis attempted to define specific occupational activities which favor the development of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/41\">",
"     41",
"    </a>",
"    ]. Analysis found increased odds ratios with greater than 30 minutes of squatting (OR = 6.9), greater than 30 minutes of kneeling (OR = 3.4), and climbing more than 10 flights of stairs per day (OR = 2.7). These results suggest that prolonged knee bending was a risk factor for osteoarthritis via mechanical loading. Similar associations with knee bending have been found in population-based studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/10,20,42,43\">",
"     10,20,42,43",
"    </a>",
"    ]. The combination of obesity and occupational bent knee activities leads to an even higher risk of knee osteoarthritis (OR = 14.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical stresses associated with certain occupations also appear to be associated with an increased risk of hip osteoarthritis. One retrospective study examining occupational hip osteoarthritis evaluated all outpatient urograms over a five year period in which both hips were visualized in males 60 to 75 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/45\">",
"     45",
"    </a>",
"    ]. Osteoarthritis was defined as joint spaces less than 2.5 mm or as the presence of a prosthetic hip replacement. The control group consisted of patients with at least 3.5 mm of joint space in the hip and no other evidence of osteoarthritis such as cysts, sclerosis, or osteophytes. Patients were interviewed for occupational activity, sports, and hobbies. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although no occupational association with osteoarthritis was found overall, analysis of severe hip osteoarthritis (defined as a joint space of less than 1.5 mm) revealed an increased odds ratio for working at least one year as a farmer (OR = 1.6) or as a construction",
"      <span class=\"nowrap\">",
"       worker/laborer",
"      </span>",
"      (OR = 1.5). Farmers with at least 10 years of work experience had higher odds ratios (OR = 2.0).",
"     </li>",
"     <li>",
"      A correlation existed between standing more than two hours and cases of osteoarthritis (OR = 1.7), a finding which remained valid after subgroup analysis for severe osteoarthritis (OR = 2.7).",
"     </li>",
"     <li>",
"      Associations with arthritis were found with more than 20 years of jobs entailing heavy lifting (OR = 2.5) or walking more than two miles per day (OR = 1.6).",
"     </li>",
"     <li>",
"      No length of exposure relationship with osteoarthritis was observed with construction workers, and no associations were found with sports activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Problems with this study include recall bias and non-standardized definitions of osteoarthritis. A similar association was found in a second study examining Japanese patients with severe OA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SPORTS ACTIVITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several uncontrolled, cross-sectional studies have compared the prevalence of osteoarthritis in groups engaged in regular exercise, utilizing radiographs as the main outcome measurement. In one review, the following sports were associated with an increased risk of osteoarthritis in the indicated joints [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Wrestling (cervical spine, knees, and elbows)",
"     </li>",
"     <li>",
"      Boxing (carpometacarpal joints)",
"     </li>",
"     <li>",
"      Pitching in baseball (shoulders and elbows)",
"     </li>",
"     <li>",
"      Cycling (patellofemoral joints)",
"     </li>",
"     <li>",
"      Recreational parachuting (spine, knees, and ankles)",
"     </li>",
"     <li>",
"      Cricket (fingers)",
"     </li>",
"     <li>",
"      Gymnastics (shoulders, wrists, and elbows)",
"     </li>",
"     <li>",
"      Ballet dancing (talar joints)",
"     </li>",
"     <li>",
"      Soccer (hips, knees, ankles, cervical spine, and talar joints)",
"     </li>",
"     <li>",
"      Football (knees, feet, and ankles)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The same sport may not yield an increased risk for the recreational participant but may increase the risk for the competitive athlete.",
"   </p>",
"   <p>",
"    The lack of suitable control groups has been a major limitation in the interpretation of these studies and casts doubt on the conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition, the cross sectional study design employed by these studies introduces significant selection bias as subjects who continue to exercise and, therefore, serve as the study group may continue to exercise by virtue of the fact that they have not developed arthritis. By comparison, those that develop arthritis stop exercising and are included in the control group.",
"   </p>",
"   <p>",
"    Evidence from a number of studies has failed to demonstrate that running increases the risk of osteoarthritis of the knee. The evidence is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link\">",
"     \"Overview of running injuries of the lower extremity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVIOUS INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joint abnormalities appear to favor the development of osteoarthritis of the knee. Hip dislocation or congenital dysplasia also enhances the risk of hip osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=see_link\">",
"     \"Clinical features and diagnosis of developmental dysplasia of the hip\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Knee injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study of the role of knee injury, for example, found that all 6 of 20 long-distance runners with knee pain who showed clinical and radiographic evidence of knee osteoarthritis had pre-existing biomechanical abnormalities of the knee (such as abnormalities of alignment, namely genu varus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    previous knee injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/52\">",
"     52",
"    </a>",
"    ]. Subsequent studies have corroborated the association between ligamentous or meniscal injury to the knee or surgical meniscectomy and subsequent increased risk for osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Among patients with documented cruciate ligament tears and painful arthritis, less than one-half recollect a knee injury [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/56\">",
"     56",
"    </a>",
"    ]. Older age at the time of trauma or surgery appears to predict a more rapid deterioration to osteoarthritis of the involved knee [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Having OA of the hands is an independent risk factor for developing OA of the operated knee, a point that suggests an interplay of heritable and environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abnormalities of the meniscus are common among patients with OA of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/59\">",
"     59",
"    </a>",
"    ]. In most cases, there is no recollected knee trauma. As an example, when 32 patients with symptomatic OA of the knee had MR imaging, some meniscal abnormality was present in 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/60\">",
"     60",
"    </a>",
"    ]. The rate of knee articular cartilage loss over two years of observation was significantly greater in those with meniscal damage at baseline. Whether meniscal damage occurred before or after the onset of symptoms could not be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amputation of one lower extremity usually increases the amount of weight borne on the unaffected limb, even when a prosthesis is used. This may account for the increased prevalence of osteoarthritis of the contralateral knee, which has been observed in unilateral amputees [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MUSCLE WEAKNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the relationship between muscle strength and osteoarthritis. Evidence supporting a role for muscle weakness as a risk factor for osteoarthritis is the finding that weakness of the quadriceps muscle group, which is common in patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/63\">",
"     63",
"    </a>",
"    ], antedated the development of knee pain and muscle atrophy in seniors and predicted the severity of radiographic and symptomatic osteoarthritis of the knee, even when adjusted for potential confounding variables [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/64\">",
"     64",
"    </a>",
"    ]. The authors of this study concluded that weakness of the quadriceps group may be etiologically related to the initiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of osteoarthritis in some patients.",
"   </p>",
"   <p>",
"    Among patients with knee pain but without radiographic changes indicative of osteoarthritis, less than average quadriceps strength and endurance may be predictive of subsequent development of arthritic changes. This was illustrated in a study of 94 such individuals whose quadriceps function was assessed by the maximum number of times they could rise from a seated position using only one leg (each leg was tested with a five minute rest between sides) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/65\">",
"     65",
"    </a>",
"    ]. The number of repetitions (total of right and left sides) was significantly less for those who developed radiographic evidence of arthritis than for those who did not (median of 17 versus 25 repetitions, respectively). Also studied was a group of 54 subjects with knee pain",
"    <strong>",
"     and",
"    </strong>",
"    radiographic arthritis at baseline; in this group with prevalent OA, there was no significant difference in quadriceps endurance between those who progressed radiographically and those who did not.",
"   </p>",
"   <p>",
"    However, in a group of patients with symptomatic osteoarthritis of their knees, quadriceps muscle strength that was less than the median for 237 patients was not associated with more rapid progression of radiographic osteoarthritis grade during 18 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/66\">",
"     66",
"    </a>",
"    ]. After adjustment for contributing factors, the rates of worsening were 0.098 and 0.153 for lower and higher muscle strength, respectively, a difference that was not statistically significant. In a hypothesis-generating analysis of subgroups, knee malalignment, either varus or valgus, was associated with significantly more radiographic progression in those with higher than in those with lower quadriceps strength at baseline. This study did not report on symptomatic or functional changes during the follow-up period, nor was muscle strength measured at other times than baseline. These provocative findings have yet to be tested as a primary hypothesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MUSCLE STRENGTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced hand strength may favor the development of osteoarthritis of the proximal joints of the hand, particularly among men. An analysis of nearly 750 subjects from the Framingham osteoarthritis study found that men with high maximal grip strength had a nearly threefold increased risk (compared with those with low maximal strength) for disease involving the proximal interphalangeal, metacarpophalangeal, and thumb base joints [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/67\">",
"     67",
"    </a>",
"    ]. By comparison, women with high maximal grip strength had a higher incidence of disease only in the metacarpophalangeal joints. No association for either men or women was observed between strength and osteoarthritis in the distal interphalangeal joints.",
"   </p>",
"   <p>",
"    In the study cited earlier, a post-hoc analysis suggested that among those with malalignment, increased quadriceps strength at baseline might predispose to more rapid progression than that seen among subjects with lower quadriceps muscle strength [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY OF RISK ASSOCIATED WITH PHYSICAL EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conclusions are supported by the available data regarding the risk for developing osteoarthritis of weight-bearing joints due to physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/21,48,68\">",
"     21,48,68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroanatomically normal joints are at increased risk of developing osteoarthritis in the absence of adequate exercise.",
"     </li>",
"     <li>",
"      Neuroanatomically normal joints are",
"      <strong>",
"       not",
"      </strong>",
"      at increased risk upon exposure to repetitive, low-impact, recreational exercise.",
"     </li>",
"     <li>",
"      Neuroanatomically abnormal joints are at increased risk upon exposure to repetitive, low impact, recreational exercise.",
"     </li>",
"     <li>",
"      Neuroanatomically normal joints are at increased risk upon exposure to repetitive, high-impact exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROPRIOCEPTIVE DEFICITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A proprioceptive deficit has been noted in humans with knee osteoarthritis and may underlie some cases of osteoarthritis. This deficit is thought to reflect damage to mechanoreceptors in or around the involved joint rather than an underlying, generalized neurologic defect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/69\">",
"     69",
"    </a>",
"    ]. The Charcot joint is a classic example of joint damage caused by the inability to appropriately sense and respond neurologically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=see_link\">",
"     \"Diabetic neuropathic arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors are implicated in the development of osteoarthritis via the results of conventional twin and non-twin sibling, population, and modern molecular studies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Genetic factors may have more influence on the expression of some subsets of osteoarthritis than others [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/71\">",
"     71",
"    </a>",
"    ]. Microsatellite DNA markers may be helpful in identifying the role of genetics in these different subsets by evaluating whether test candidate genes are responsible for or are linked to the illness in familial disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Twin and non-twin sibling studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A genetic influence for osteoarthritis of the hands and knees was noted in a study using screening radiographs of 500 unselected female twins aged 45 to 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/74\">",
"     74",
"    </a>",
"    ]. Correlations of osteoarthritis were consistently twofold higher in 130 pairs of identical compared with non-identical twins. The influence of genetic factors was estimated to be between 39 to 65 percent, independent of known environmental or demographic variables [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/74\">",
"     74",
"    </a>",
"    ]. Both the tibiofemoral and patellofemoral compartments of the knee appeared to be influenced by genetic factors, but the proximal interphalangeal joints failed to demonstrate a genetic component. Other twin studies have found that the degree of influence of genetic factors for the development of osteoarthritis of the hip is approximately 60 percent, while that for cervical and lumbar disc degeneration is 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A genetic component for the development of hand and lumbar spine, but not knee or hip, osteoarthritis was found in a study of non-twin siblings. In one report of 118 subjects with osteoarthritis and 257 non-twin siblings, the influence of genetic factors for hand and back osteoarthritis was approximately 55 and 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/72\">",
"     72",
"    </a>",
"    ]. In another study of nearly 3000 people with OA affecting the carpal metacarpal joint of the thumb or the interphalangeal joints of the fingers, there was a twofold increase in risk for sisters of women with hand OA and a five- to sevenfold increase in the relative risk of having arthritis if the sibling had \"severe\" OA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Genome-wide scanning",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Hand OA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome-wide scanning in 296 pedigrees was performed in order to identify loci associated with radiographic osteoarthritis of the hands [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/78\">",
"     78",
"    </a>",
"    ]. Eight sites of potential linkage were found on chromosomes 1, 7, 9, 13, and 19. The most tightly linked was a region on the short end of chromosome 1. Subsequent analysis in 267 pedigrees suggested that OA of specific joints of the hands, particularly the first carpometacarpal joint and the distal interphalangeal (DIP) joints, was linked to different sites [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other investigators identified a locus on chromosome 11 that was associated with the risk of osteoarthritis of the hip in the female members of 481 families that had at least one severely affected index case (requiring total hip arthroplasty) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/80\">",
"     80",
"    </a>",
"    ]. Two sites within the 11q region were suggested by more detailed mapping of this region [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/81\">",
"     81",
"    </a>",
"    ]. Other sites of interest include ones on chromosome 4, two on chromosome 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/82\">",
"     82",
"    </a>",
"    ], and ones on chromosomes 2 and 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Idiopathic OA of the hands, specifically of the distal interphalangeal and first carpal-metacarpal joints in patients and families in Iceland, was linked to regions on chromosomes 4, 3, and 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/84\">",
"     84",
"    </a>",
"    ]. A mutation in the gene for a noncollagenous matrix protein, matrilin-3 (MATN3), segregated with hand OA in several families. In the Icelandic population, approximately 2 percent of those with hand OA carry the mutated gene; carriage confers a twofold increase in the relative risk for hand OA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Knee OA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genome-wide screening of unrelated women with OA of the knee and controls in British and Canadians of European ancestry noted a reproducible association with a marker within the gene for LRCH1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/85\">",
"     85",
"    </a>",
"    ]. This study initially identified a potential association between 335 women with OA who were awaiting or had undergone total knee replacement and a control group of equal size. Replication of the association was observed in two additional groups of 246 and 211 cases of OA of the knee in the UK and Canada, respectively, and unaffected controls. A polymorphism in LRCH1 on chromosome 13 was 1 of 31 single nucleotide polymorphisms that was significantly more frequent in cases than controls. The marker (rs91242a",
"    <span class=\"nowrap\">",
"     C/T)",
"    </span>",
"    allele frequency was significantly higher in cases than controls, 23 and 17 percent, respectively, (OR = 1.44) in the initial study, and exhibited the strongest and most consistent effect of the initially identified loci when all three samples were considered. The function of the LRCH1 gene product is unknown, but it has regions that are homologous to those of actin-binding proteins that regulate cells shape and participate in intracellular signaling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Haplotype associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary generalized \"nodal\" osteoarthritis, characterized by Heberden's nodes, Bouchard's nodes, and involvement of the hips and knees, appears to have a genetic component [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/86\">",
"     86",
"    </a>",
"    ]. This form of osteoarthritis has been associated with HLA-A1,B8 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/87\">",
"     87",
"    </a>",
"    ] and HLA-B8 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/88\">",
"     88",
"    </a>",
"    ] haplotypes and with alpha-1 antitrypsin isoforms; however, several studies have not found this association [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/89,90\">",
"     89,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Mutations in proteins involved in bone or articular cartilage structure or metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential genetic abnormalities which predispose to osteoarthritis include structural defects in collagen and alterations in cartilage or bone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/71\">",
"     71",
"    </a>",
"    ]. These defects may influence the effect of additional risk factors, such as obesity, on the development of osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     COL2A1 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proposed candidate osteoarthritic genes include the collagen genes that encode for type II collagen. A number of studies have shown linkage in different families and in a population-based study between generalized osteoarthritis (usually with mild chondrodysplasia) and mutations in the COL2A1 gene on chromosome 12 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/91-95\">",
"     91-95",
"    </a>",
"    ]. In one family, for example, a single base mutation in COL2A1 was noted in all affected members of a family but in none of the unaffected members or unrelated individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/93\">",
"     93",
"    </a>",
"    ]. Mutations in the COL2A1 gene have also been linked to the Stickler syndrome. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Stickler syndrome'",
"    </a>",
"    below.).",
"   </p>",
"   <p>",
"    Evidence of pathogenicity comes from an animal study in which insertion of the mutant human COL2A1 gene into mice lacking the normal complement of the murine equivalent gene produced early degeneration of vertebral discs and osteoarthritic changes in peripheral joints [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A different mutation in the COL2A1 gene in a single extended family has been associated with several clinical syndromes affecting the hip, including premature osteoarthritis, osteonecrosis, and Legg-Calv&eacute;-Perthes disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link&amp;anchor=H435805#H435805\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Other causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Other extracellular matrix proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic nature of primary generalized osteoarthritis may be heterogeneous, and mutations in genes other than COL2A1 may be responsible. The role of mutations in genes encoding minor collagen types and extracellular matrix proteins, such as aggrecan, decorin, and the link protein, therefore, needs to be further investigated.",
"   </p>",
"   <p>",
"    The gene for one such matrix protein, asporin, appears to be a promising candidate. This was illustrated in a multifaceted study of polymorphisms of the asporin gene in a Japanese population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/98\">",
"     98",
"    </a>",
"    ]. An exploratory investigation suggested that an allele that increases the number of aspartic acid residues in one portion of the molecule from 13 (D13-allele) to 14 residues (D14-allele) was associated with osteoarthritis of the knee. A subsequent study in 393 patients with symptomatic OA of the knee and 374 controls indicated that having one or more of the asporin D14-alleles conferred a twofold increased risk of symptomatic and radiographic osteoarthritis compared with the more common D13-allele (OR 2.00, 95% CI 1.4-2.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/98\">",
"     98",
"    </a>",
"    ]. A somewhat smaller, but also statistically significant, increase in risk was also seen for the asporin D14-allele and OA of the hip (OR 1.71, 95% CI 1.1-2.6).",
"   </p>",
"   <p>",
"    In vitro, asporin produced from the D14-allele suppresses transforming growth factor-beta (TGF-beta) stimulated synthesis of the major articular cartilage structural proteins, type-II collagen and aggrecan, by cultured chondrocytes. This and a demonstrated ability of asporin to physically bind to TGF-beta lend biologic plausibility to the observed association between the asporin genetic polymorphism and OA of the hip and knee [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The D14-allele of asporin may not be a major contributor to risk in other populations. This was illustrated in a study in the United Kingdom of 1247 patients who had joint replacement surgery for OA and 748 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/99\">",
"     99",
"    </a>",
"    ]. In this predominantly Caucasian population, the D14-allele frequency was greater and the D13-allele frequency was less than those in the Japanese population. Overall, there was no significant association found in this population between asporin aspartate repeat genotype and osteoarthritis. Among various subsets defined by sex and affected joint, a possible association with the D14-allele in men with OA of the hip (odds ratio 1.48, 95% CI 1.05-2.01) was noted. Exploration of the contribution of asporin gene polymorphism to OA in other populations will be of interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Endocrine/metabolic genetic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting evidence exists concerning the association of specific polymorphisms of the genes for the vitamin D receptor and the estrogen receptor and a predisposition for OA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/100-105\">",
"     100-105",
"    </a>",
"    ]. In a well-designed case control study, however, no association was observed between OA and these polymorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report noted an increased frequency of heterozygous carriage of the hemochromatosis HFE gene allele (C282Y) in older people with osteoarthritis of the hands compared with healthy young controls (16 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/106\">",
"     106",
"    </a>",
"    ]. No significant difference in frequency of another hemochromatosis-associated allele (HFE H63D) was found in the OA affected and control groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=see_link&amp;anchor=H2#H2\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'The HFE gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic linkage to a region on chromosome 2 (2q13-32) has been noted in severe osteoarthritis (eg, resulting in joint replacement) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/106\">",
"     106",
"    </a>",
"    ]. A cluster of interleukin 1 (IL-1) related genes, those for IL-1&alpha;, IL-1&beta;, and the IL-1 receptor antagonist (IL1RN), lies in this region of the chromosome. Limited data suggest that polymorphisms of the IL-1B (-511T allele) and IL1RN (variable number of terminal repeats [VNTR] 2 allele) genes are associated with radiographic osteoarthritis of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/107\">",
"     107",
"    </a>",
"    ]. An association with the IL-1 gene cluster has biologic plausibility because of the catabolic effects that IL-1 has on chondrocytes and articular cartilage, particularly the enhanced production of matrix degrading metalloproteinases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of osteoarthritis\", section on 'Catabolic cytokines'",
"    </a>",
"    .) Further study of this putative association in other populations is anticipated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AACT, ADAM12, BMP2, ESR1, CILP, COX2, OPG, TNFAIP6, and FRZB genes may be associated with an increased susceptibility to OA to a variable degree in women",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    men, and the ADAM12, CILP, OPG, and TNA genes may be related to the risk of progression of radiographic OA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/108-110\">",
"     108-110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Stickler syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary arthro-ophthalmopathy (Stickler syndrome) is a familial form of premature osteoarthritis characterized by vitreous degeneration, retinal detachment, and premature degenerative joint disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]; it is a relatively rare autosomal dominant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/71\">",
"     71",
"    </a>",
"    ]. Using linkage analysis, Stickler syndrome is linked to type II procollagen gene (COL2A1) in 25 to 50 percent of involved families [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/113-115\">",
"     113-115",
"    </a>",
"    ]; in some of the remaining families, the defect is in type XI collagen (COL11A2) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link&amp;anchor=H18#H18\">",
"     \"Syndromes with craniofacial abnormalities\", section on 'Stickler and Marshall syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Familial chondrocalcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial chondrocalcinosis is an inherited form of premature osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/117\">",
"     117",
"    </a>",
"    ]. In this disorder, calcium-containing crystals are deposited in joint tissue which progresses to severe degenerative osteoarthritis at an early age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. An autosomal dominant mode of inheritance is observed, with age of onset between the second and fifth decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=see_link\">",
"     \"Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Linkage analysis has isolated suspect genetic areas in familial chondrocalcinosis and early osteoarthritis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A genetic linkage has been found with chromosome 8q in a large New England family [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/71,120\">",
"       71,120",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second family with chondrocalcinosis and recurrent childhood seizures has been described with linkage to markers on chromosome 5p [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early developments of osteoarthritis, spondyloepiphyseal dysplasia, and CPPD have been linked to a point mutation in a type II procollagen gene [",
"      <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several forms of familial osteoarthritis associated with chondrodysplasia have also been noted. They also have an autosomal dominant pattern of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/123\">",
"     123",
"    </a>",
"    ]. Osteoarthritis is also a feature of familial hydroxyapatite deposition disease, spondyloepiphyseal dysplasia, Kniest dysplasia, multiple epiphyseal dysplasia, and metaphyseal chondrodysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ACROMEGALY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acromegaly has been associated with the development of secondary osteoarthritis, presumably due to the effects of elevated growth hormone levels on bone and cartilage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    .) However, whether a true causal relationship exists between these disorders remains unclear. Most studies purporting this association lack a comparison between older acromegalic patients and an older control population [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/125\">",
"     125",
"    </a>",
"    ]. In addition, the incidence of osteoarthritis in patients with growth hormone deficiency has not been studied.",
"   </p>",
"   <p>",
"    In an attempt to overcome these design deficiencies, one review evaluated the prevalence of osteoarthritis in 26 patients with acromegaly (mean age of 73 years), 22 with growth hormone deficiency (mean age of 69 years), and 260 healthy controls (age range of 70 to 75 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/126\">",
"     126",
"    </a>",
"    ]. The prevalence of osteoarthritis as assessed by hand and knee radiographs was",
"    <strong>",
"     no",
"    </strong>",
"    greater in the acromegalic patients than in the controls except in the proximal interphalangeal joints. In addition, patients with growth hormone deficiency had a significantly decreased prevalence of osteoarthritis compared with controls. These data may have been biased by the age of study and by treatment for acromegaly, which may have affected the development of osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     CALCIUM CRYSTALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular calcium-containing crystals including calcium pyrophosphate dihydrate (CPPD) deposition and basic calcium phosphate (BCP) (hydroxyapatite, octacalcium phosphate, tricalcium phosphate) appear to coexist with cartilage damage in patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/127\">",
"     127",
"    </a>",
"    ]. However, it has not yet been established if this relationship is pathogenetically important or if it is an epiphenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/128,129\">",
"     128,129",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=see_link\">",
"     \"Pathogenesis of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both CPPD and BCP crystals are commonly found in osteoarthritic cartilage and have been observed within chondrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/130-133\">",
"     130-133",
"    </a>",
"    ]. The prevalence of BCP crystals in the synovial fluid of patients with knee osteoarthritis has been noted to be between 30 and 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. In addition, CPPD crystals were noted in 70 percent of patients with knee osteoarthritis and pain refractory to nonsteroidal antiinflammatory drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraarticular corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/136\">",
"     136",
"    </a>",
"    ]. Calcium-containing crystals have also been frequently described in osteoarthritis involving the shoulders, wrists, and elbows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/43/29370/abstract/118\">",
"     118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"       \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4497799\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarthritis results from a complex interplay of multiple factors, many of which have been linked to osteoarthritis (OA) in epidemiologic studies, such as aging, occupation, trauma, and repetitive, small insults over time. These associations are strongest for OA of the knee and hand and are less strong for that of the hip. Rarely, inherited conditions may predispose individuals to develop osteoarthritis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors and possible causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Age and gender are important risk factors for OA. Advanced age is one of the strongest risk factors, and numerous studies have found that female sex is associated with an increased relative risk of OA (estimated 2.6) after adjustment for age, weight, and smoking. Studies in women have also found that higher bone mass is associated with an increased risk of hip osteoarthritis and have shown an inverse relationship between receipt of long term postmenopausal hormone therapy and osteoarthritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Age'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Female sex'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Lack of osteoporosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Estrogen replacement therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obesity may be the strongest modifiable risk factor for OA, but the risk varies by joint. The association is strongest for the knees and hands but is less consistent for the hip. It is likely that even modest weight loss will provide some benefit in modifying risk. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Obesity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Knee'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Hand'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Hip'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical activities related to both occupation and sports affect the risk of OA, as do previous injuries and muscle strength. Mechanisms for the association between specific occupations and OA of the knees, hands, or hips may involve joint loading and repetitive damage over time. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Occupation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Sports activities'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Previous injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Muscle weakness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Muscle strength'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Summary of risk associated with physical exercise'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Taken together, the studies on physical activity indicate that:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neuroanatomically normal joints are at increased risk of developing osteoarthritis in the absence of adequate exercise.",
"     </li>",
"     <li>",
"      Neuroanatomically normal joints are",
"      <strong>",
"       not",
"      </strong>",
"      at increased risk upon exposure to repetitive, low-impact, recreational exercise.",
"     </li>",
"     <li>",
"      Neuroanatomically abnormal joints are at increased risk upon exposure to repetitive, low impact, recreational exercise.",
"     </li>",
"     <li>",
"      Neuroanatomically normal joints are at increased risk upon exposure to repetitive, high-impact exercise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic factors have been implicated in the development of OA, based upon conventional twin and non-twin sibling, population, and modern molecular studies. Such factors may have more influence on the expression of some subsets of OA than others. As examples, primary generalized \"nodal\" OA, characterized by Heberden's nodes, Bouchard's nodes, and involvement of the hips and knees, appears to have a genetic component; and genetic abnormalities in collagen or alterations in cartilage or bone metabolism may also predispose to OA. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Genetic factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Genome-wide scanning'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H30\">",
"       'Mutations in proteins involved in bone or articular cartilage structure or metabolism'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Stickler syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inherited and acquired metabolic conditions, particularly those associated with calcium deposition, can also influence the development of OA, including calcium crystal diseases, familial chondrocalcinosis, acromegaly, and other disorders. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Calcium crystals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Familial chondrocalcinosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H38\">",
"       'Acromegaly'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/1\">",
"      Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350:503.",
"     </a>",
"    </li>",
"    <li>",
"     Brandt K. Osteoarthritis: Clinical patterns and pathology. In: Textbook of Rheumatology, Fifth Edition, Kelley WN, Harris ED Jr, Ruddy S, Sledge CE (Eds), W.B. Saunders, Philadelphia 1997. p.1383.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/3\">",
"      Jordan JM, Luta G, Renner JB, et al. Self-reported functional status in osteoarthritis of the knee in a rural southern community: the role of sociodemographic factors, obesity, and knee pain. Arthritis Care Res 1996; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/4\">",
"      Heli&ouml;vaara M, M&auml;kel&auml; M, Impivaara O, et al. Association of overweight, trauma and workload with coxarthrosis. A health survey of 7,217 persons. Acta Orthop Scand 1993; 64:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/5\">",
"      Felson DT, Zhang Y, Anthony JM, et al. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992; 116:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/6\">",
"      Hartz AJ, Fischer ME, Bril G, et al. The association of obesity with joint pain and osteoarthritis in the HANES data. J Chronic Dis 1986; 39:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/7\">",
"      Lawrence JS, Bremner JM, Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis 1966; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/8\">",
"      Davis MA, Ettinger WH, Neuhaus JM, Hauck WW. Sex differences in osteoarthritis of the knee. The role of obesity. Am J Epidemiol 1988; 127:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/9\">",
"      Maillefert JF, Gueguen A, Monreal M, et al. Sex differences in hip osteoarthritis: results of a longitudinal study in 508 patients. Ann Rheum Dis 2003; 62:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/10\">",
"      Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol 1988; 128:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/11\">",
"      Felson DT, Anderson JJ, Naimark A, et al. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med 1988; 109:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/12\">",
"      KELLGREN JH. Osteoarthrosis in patients and populations. Br Med J 1961; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/13\">",
"      Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: the Chingford Study. J Rheumatol 1993; 20:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/14\">",
"      Spector TD, Hart DJ, Doyle DV. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: the effect of obesity. Ann Rheum Dis 1994; 53:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/15\">",
"      Ving&aring;rd E. Overweight predisposes to coxarthrosis. Body-mass index studied in 239 males with hip arthroplasty. Acta Orthop Scand 1991; 62:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/16\">",
"      Kraus JF, D'Ambrosia RD, Smith EG, et al. An epidemiological study of severe osteoarthritis. Orthopedics 1978; 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/17\">",
"      Saville PD, Dickson J. Age and weight in osteoarthritis of the hip. Arthritis Rheum 1968; 11:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/18\">",
"      Losina E, Walensky RP, Reichmann WM, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med 2011; 154:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/19\">",
"      Hart DJ, Doyle DV, Spector TD. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum 1999; 42:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/20\">",
"      McAlindon TE, Wilson PW, Aliabadi P, et al. Level of physical activity and the risk of radiographic and symptomatic knee osteoarthritis in the elderly: the Framingham study. Am J Med 1999; 106:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/21\">",
"      Felson DT, Niu J, Clancy M, et al. Effect of recreational physical activities on the development of knee osteoarthritis in older adults of different weights: the Framingham Study. Arthritis Rheum 2007; 57:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/22\">",
"      Nguyen US, Zhang Y, Zhu Y, et al. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data. Ann Intern Med 2011; 155:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/23\">",
"      Karlson EW, Mandl LA, Aweh GN, et al. Total hip replacement due to osteoarthritis: the importance of age, obesity, and other modifiable risk factors. Am J Med 2003; 114:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/24\">",
"      Flugsrud GB, Nordsletten L, Espehaug B, et al. The impact of body mass index on later total hip arthroplasty for primary osteoarthritis: a cohort study in 1.2 million persons. Arthritis Rheum 2006; 54:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/25\">",
"      Gelber AC, Hochberg MC, Mead LA, et al. Body mass index in young men and the risk of subsequent knee and hip osteoarthritis. Am J Med 1999; 107:542.",
"     </a>",
"    </li>",
"    <li>",
"     Lindsay R. Estrogen deficiency. In: Osteoporosis: Etiology, Diagnosis, and Management, Second Edition, Riggs BL, Melton LJ (Eds), Lippincott-Raven Publishers, 1995. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/27\">",
"      Cooper C, Cook PL, Osmond C, et al. Osteoarthritis of the hip and osteoporosis of the proximal femur. Ann Rheum Dis 1991; 50:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/28\">",
"      Nevitt MC, Lane NE, Scott JC, et al. Radiographic osteoarthritis of the hip and bone mineral density. The Study of Osteoporotic Fractures Research Group. Arthritis Rheum 1995; 38:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/29\">",
"      Hart DJ, Mootoosamy I, Doyle DV, Spector TD. The relationship between osteoarthritis and osteoporosis in the general population: the Chingford Study. Ann Rheum Dis 1994; 53:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/30\">",
"      Zhang Y, Hannan MT, Chaisson CE, et al. Bone mineral density and risk of incident and progressive radiographic knee osteoarthritis in women: the Framingham Study. J Rheumatol 2000; 27:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/31\">",
"      Rosner IA, Goldberg VM, Moskowitz RW. Estrogens and osteoarthritis. Clin Orthop Relat Res 1986; :77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/32\">",
"      Tsai CL, Liu TK. Estradiol-induced knee osteoarthrosis in ovariectomized rabbits. Clin Orthop Relat Res 1993; :295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/33\">",
"      SILBERBERG M, SILBERBERG R. Modifying action of estrogen on the evolution of osteoarthrosis in mice of different ages. Endocrinology 1963; 72:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/34\">",
"      Turner AS, Athanasiou KA, Zhu CF, et al. Biochemical effects of estrogen on articular cartilage in ovariectomized sheep. Osteoarthritis Cartilage 1997; 5:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/35\">",
"      Hannan MT, Felson DT, Anderson JJ, et al. Estrogen use and radiographic osteoarthritis of the knee in women. The Framingham Osteoarthritis Study. Arthritis Rheum 1990; 33:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/36\">",
"      Samanta A, Jones A, Regan M, et al. Is osteoarthritis in women affected by hormonal changes or smoking? Br J Rheumatol 1993; 32:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/37\">",
"      Nevitt MC, Cummings SR, Lane NE, et al. Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1996; 156:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/38\">",
"      Felson DT, Zhang Y, Hannan MT, et al. The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum 1995; 38:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/39\">",
"      Oliveria SA, Felson DT, Klein RA, et al. Estrogen replacement therapy and the development of osteoarthritis. Epidemiology 1996; 7:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/40\">",
"      Nevitt MC, Felson DT, Williams EN, Grady D. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001; 44:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/41\">",
"      Cooper C, McAlindon T, Coggon D, et al. Occupational activity and osteoarthritis of the knee. Ann Rheum Dis 1994; 53:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/42\">",
"      Felson DT. The epidemiology of knee osteoarthritis: results from the Framingham Osteoarthritis Study. Semin Arthritis Rheum 1990; 20:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/43\">",
"      Zhang Y, Hunter DJ, Nevitt MC, et al. Association of squatting with increased prevalence of radiographic tibiofemoral knee osteoarthritis: the Beijing Osteoarthritis Study. Arthritis Rheum 2004; 50:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/44\">",
"      Coggon D, Croft P, Kellingray S, et al. Occupational physical activities and osteoarthritis of the knee. Arthritis Rheum 2000; 43:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/45\">",
"      Croft P, Cooper C, Wickham C, Coggon D. Osteoarthritis of the hip and occupational activity. Scand J Work Environ Health 1992; 18:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/46\">",
"      Yoshimura N, Sasaki S, Iwasaki K, et al. Occupational lifting is associated with hip osteoarthritis: a Japanese case-control study. J Rheumatol 2000; 27:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/47\">",
"      Panush RS. Does exercise cause arthritis? Long-term consequences of exercise on the musculoskeletal system. Rheum Dis Clin North Am 1990; 16:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/48\">",
"      Lane NE. Exercise: a cause of osteoarthritis. J Rheumatol Suppl 1995; 43:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/49\">",
"      Murphy SB, Ganz R, M&uuml;ller ME. The prognosis in untreated dysplasia of the hip. A study of radiographic factors that predict the outcome. J Bone Joint Surg Am 1995; 77:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/50\">",
"      Jacobsen S, Sonne-Holm S. Hip dysplasia: a significant risk factor for the development of hip osteoarthritis. A cross-sectional survey. Rheumatology (Oxford) 2005; 44:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/51\">",
"      Reijman M, Hazes JM, Pols HA, et al. Acetabular dysplasia predicts incident osteoarthritis of the hip: the Rotterdam study. Arthritis Rheum 2005; 52:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/52\">",
"      McDermott M, Freyne P. Osteoarthrosis in runners with knee pain. Br J Sports Med 1983; 17:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/53\">",
"      von Porat A, Roos EM, Roos H. High prevalence of osteoarthritis 14 years after an anterior cruciate ligament tear in male soccer players: a study of radiographic and patient relevant outcomes. Ann Rheum Dis 2004; 63:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/54\">",
"      Boszotta H, Helperstorfer W, K&ouml;lndorfer G, et al. [Long-term results of arthroscopic meniscectomy]. Aktuelle Traumatol 1994; 24:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/55\">",
"      Neyret P, Donell ST, Dejour H. Osteoarthritis of the knee following meniscectomy. Br J Rheumatol 1994; 33:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/56\">",
"      Hill CL, Seo GS, Gale D, et al. Cruciate ligament integrity in osteoarthritis of the knee. Arthritis Rheum 2005; 52:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/57\">",
"      Doherty M, Watt I, Dieppe P. Influence of primary generalised osteoarthritis on development of secondary osteoarthritis. Lancet 1983; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/58\">",
"      Englund M, Paradowski PT, Lohmander LS. Association of radiographic hand osteoarthritis with radiographic knee osteoarthritis after meniscectomy. Arthritis Rheum 2004; 50:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/59\">",
"      Hunter DJ, Zhang YQ, Niu JB, et al. The association of meniscal pathologic changes with cartilage loss in symptomatic knee osteoarthritis. Arthritis Rheum 2006; 54:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/60\">",
"      Berthiaume MJ, Raynauld JP, Martel-Pelletier J, et al. Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis 2005; 64:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/61\">",
"      Burke MJ, Roman V, Wright V. Bone and joint changes in lower limb amputees. Ann Rheum Dis 1978; 37:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/62\">",
"      Melzer I, Yekutiel M, Sukenik S. Comparative study of osteoarthritis of the contralateral knee joint of male amputees who do and do not play volleyball. J Rheumatol 2001; 28:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/63\">",
"      Fisher NM, Kame VD Jr, Rouse L, Pendergast DR. Quantitative evaluation of a home exercise program on muscle and functional capacity of patients with osteoarthritis. Am J Phys Med Rehabil 1994; 73:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/64\">",
"      Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997; 127:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/65\">",
"      Thorstensson CA, Petersson IF, Jacobsson LT, et al. Reduced functional performance in the lower extremity predicted radiographic knee osteoarthritis five years later. Ann Rheum Dis 2004; 63:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/66\">",
"      Sharma L, Dunlop DD, Cahue S, et al. Quadriceps strength and osteoarthritis progression in malaligned and lax knees. Ann Intern Med 2003; 138:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/67\">",
"      Chaisson CE, Zhang Y, Sharma L, et al. Grip strength and the risk of developing radiographic hand osteoarthritis: results from the Framingham Study. Arthritis Rheum 1999; 42:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/68\">",
"      Buckwalter JA. Osteoarthritis and articular cartilage use, disuse, and abuse: experimental studies. J Rheumatol Suppl 1995; 43:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/69\">",
"      Sharma L, Pai YC. Impaired proprioception and osteoarthritis. Curr Opin Rheumatol 1997; 9:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/70\">",
"      Wordsworth P. Genes and arthritis. Br Med Bull 1995; 51:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/71\">",
"      Holderbaum D, Haqqi TM, Moskowitz RW. Genetics and osteoarthritis: exposing the iceberg. Arthritis Rheum 1999; 42:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/72\">",
"      Bijkerk C, Houwing-Duistermaat JJ, Valkenburg HA, et al. Heritabilities of radiologic osteoarthritis in peripheral joints and of disc degeneration of the spine. Arthritis Rheum 1999; 42:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/73\">",
"      Ingvarsson T, Stef&aacute;nsson SE, Hallgr&iacute;msd&oacute;ttir IB, et al. The inheritance of hip osteoarthritis in Iceland. Arthritis Rheum 2000; 43:2785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/74\">",
"      Spector TD, Cicuttini F, Baker J, et al. Genetic influences on osteoarthritis in women: a twin study. BMJ 1996; 312:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/75\">",
"      MacGregor AJ, Antoniades L, Matson M, et al. The genetic contribution to radiographic hip osteoarthritis in women: results of a classic twin study. Arthritis Rheum 2000; 43:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/76\">",
"      Sambrook PN, MacGregor AJ, Spector TD. Genetic influences on cervical and lumbar disc degeneration: a magnetic resonance imaging study in twins. Arthritis Rheum 1999; 42:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/77\">",
"      Jonsson H, Manolescu I, Stefansson SE, et al. The inheritance of hand osteoarthritis in Iceland. Arthritis Rheum 2003; 48:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/78\">",
"      Demissie S, Cupples LA, Myers R, et al. Genome scan for quantity of hand osteoarthritis: the Framingham Study. Arthritis Rheum 2002; 46:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/79\">",
"      Hunter DJ, Demissie S, Cupples LA, et al. A genome scan for joint-specific hand osteoarthritis susceptibility: The Framingham Study. Arthritis Rheum 2004; 50:2489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/80\">",
"      Chapman K, Mustafa Z, Irven C, et al. Osteoarthritis-susceptibility locus on chromosome 11q, detected by linkage. Am J Hum Genet 1999; 65:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/81\">",
"      Chapman K, Mustafa Z, Dowling B, et al. Finer linkage mapping of primary hip osteoarthritis susceptibility on chromosome 11q in a cohort of affected female sibling pairs. Arthritis Rheum 2002; 46:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/82\">",
"      Forster T, Chapman K, Marcelline L, et al. Finer linkage mapping of primary osteoarthritis susceptibility loci on chromosomes 4 and 16 in families with affected women. Arthritis Rheum 2004; 50:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/83\">",
"      Livshits G, Kato BS, Zhai G, et al. Genomewide linkage scan of hand osteoarthritis in female twin pairs showing replication of quantitative trait loci on chromosomes 2 and 19. Ann Rheum Dis 2007; 66:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/84\">",
"      Stef&aacute;nsson SE, J&oacute;nsson H, Ingvarsson T, et al. Genomewide scan for hand osteoarthritis: a novel mutation in matrilin-3. Am J Hum Genet 2003; 72:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/85\">",
"      Spector TD, Reneland RH, Mah S, et al. Association between a variation in LRCH1 and knee osteoarthritis: a genome-wide single-nucleotide polymorphism association study using DNA pooling. Arthritis Rheum 2006; 54:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/86\">",
"      Marks JS, Stewart IM, Hardinge K. Primary osteoathrosis of the hip and Heberden's nodes. Ann Rheum Dis 1979; 38:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/87\">",
"      Pattrick M, Manhire A, Ward AM, Doherty M. HLA-A, B antigens and alpha 1-antitrypsin phenotypes in nodal generalised osteoarthritis and erosive osteoarthritis. Ann Rheum Dis 1989; 48:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/88\">",
"      Brodsky A, Appelboom T, Govaerts A, Famaey JP. [HLA antigens and Heberden nodes (author's transl)]. Acta Rhumatol Belg 1979; 3:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/89\">",
"      Ercilla MG, Brancos MA, Breysse Y, et al. HLA antigens in Forestier's disease, ankylosing spondylitis, and polyarthrosis of the hands. J Rheumatol Suppl 1977; 3:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/90\">",
"      Benavides G, Cervantes A, Silva B, et al. HLA and Heberden's nodes in Mexican Mestizos. Clin Rheumatol 1985; 4:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/91\">",
"      Palotie A, V&auml;is&auml;nen P, Ott J, et al. Predisposition to familial osteoarthrosis linked to type II collagen gene. Lancet 1989; 1:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/92\">",
"      Knowlton RG, Katzenstein PL, Moskowitz RW, et al. Genetic linkage of a polymorphism in the type II procollagen gene (COL2A1) to primary osteoarthritis associated with mild chondrodysplasia. N Engl J Med 1990; 322:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/93\">",
"      Ala-Kokko L, Baldwin CT, Moskowitz RW, Prockop DJ. Single base mutation in the type II procollagen gene (COL2A1) as a cause of primary osteoarthritis associated with a mild chondrodysplasia. Proc Natl Acad Sci U S A 1990; 87:6565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/94\">",
"      Vikkula M, Palotie A, Ritvaniemi P, et al. Early-onset osteoarthritis linked to the type II procollagen gene. Detailed clinical phenotype and further analyses of the gene. Arthritis Rheum 1993; 36:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/95\">",
"      Uitterlinden AG, Burger H, van Duijn CM, et al. Adjacent genes, for COL2A1 and the vitamin D receptor, are associated with separate features of radiographic osteoarthritis of the knee. Arthritis Rheum 2000; 43:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/96\">",
"      Sahlman J, Pitk&auml;nen MT, Prockop DJ, et al. A human COL2A1 gene with an Arg519Cys mutation causes osteochondrodysplasia in transgenic mice. Arthritis Rheum 2004; 50:3153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/97\">",
"      Su P, Li R, Liu S, et al. Age at onset-dependent presentations of premature hip osteoarthritis, avascular necrosis of the femoral head, or Legg-Calv&eacute;-Perthes disease in a single family, consequent upon a p.Gly1170Ser mutation of COL2A1. Arthritis Rheum 2008; 58:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/98\">",
"      Kizawa H, Kou I, Iida A, et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet 2005; 37:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/99\">",
"      Mustafa Z, Dowling B, Chapman K, et al. Investigating the aspartic acid (D) repeat of asporin as a risk factor for osteoarthritis in a UK Caucasian population. Arthritis Rheum 2005; 52:3502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/100\">",
"      Loughlin J, Sinsheimer JS, Mustafa Z, et al. Association analysis of the vitamin D receptor gene, the type I collagen gene COL1A1, and the estrogen receptor gene in idiopathic osteoarthritis. J Rheumatol 2000; 27:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/101\">",
"      Keen RW, Hart DJ, Lanchbury JS, Spector TD. Association of early osteoarthritis of the knee with a Taq I polymorphism of the vitamin D receptor gene. Arthritis Rheum 1997; 40:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/102\">",
"      Uitterlinden AG, Burger H, Huang Q, et al. Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. J Clin Invest 1997; 100:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/103\">",
"      Ushiyama T, Ueyama H, Inoue K, et al. Estrogen receptor gene polymorphism and generalized osteoarthritis. J Rheumatol 1998; 25:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/104\">",
"      Bergink AP, van Meurs JB, Loughlin J, et al. Estrogen receptor alpha gene haplotype is associated with radiographic osteoarthritis of the knee in elderly men and women. Arthritis Rheum 2003; 48:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/105\">",
"      Jordan KM, Syddall H, Dennison EM, et al. Birthweight, vitamin D receptor gene polymorphism, and risk of lumbar spine osteoarthritis. J Rheumatol 2005; 32:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/106\">",
"      Ross JM, Kowalchuk RM, Shaulinsky J, et al. Association of heterozygous hemochromatosis C282Y gene mutation with hand osteoarthritis. J Rheumatol 2003; 30:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/107\">",
"      Meulenbelt I, Seymour AB, Nieuwland M, et al. Association of the interleukin-1 gene cluster with radiographic signs of osteoarthritis of the hip. Arthritis Rheum 2004; 50:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/108\">",
"      Valdes AM, Van Oene M, Hart DJ, et al. Reproducible genetic associations between candidate genes and clinical knee osteoarthritis in men and women. Arthritis Rheum 2006; 54:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/109\">",
"      Min JL, Meulenbelt I, Riyazi N, et al. Association of the Frizzled-related protein gene with symptomatic osteoarthritis at multiple sites. Arthritis Rheum 2005; 52:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/110\">",
"      Lane NE, Lian K, Nevitt MC, et al. Frizzled-related protein variants are risk factors for hip osteoarthritis. Arthritis Rheum 2006; 54:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/111\">",
"      STICKLER GB, BELAU PG, FARRELL FJ, et al. HEREDITARY PROGRESSIVE ARTHRO-OPHTHALMOPATHY. Mayo Clin Proc 1965; 40:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/112\">",
"      Rai A, Wordsworth P, Coppock JS, et al. Hereditary arthro-ophthalmopathy (Stickler syndrome): a diagnosis to consider in familial premature osteoarthritis. Br J Rheumatol 1994; 33:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/113\">",
"      Francomano CA, Liberfarb RM, Hirose T, et al. The Stickler syndrome: evidence for close linkage to the structural gene for type II collagen. Genomics 1987; 1:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/114\">",
"      Knowlton RG, Weaver EJ, Struyk AF, et al. Genetic linkage analysis of hereditary arthro-ophthalmopathy (Stickler syndrome) and the type II procollagen gene. Am J Hum Genet 1989; 45:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/115\">",
"      Wilkin DJ, Mortier GR, Johnson CL, et al. Correlation of linkage data with phenotype in eight families with Stickler syndrome. Am J Med Genet 1998; 80:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/116\">",
"      Sirko-Osadsa DA, Murray MA, Scott JA, et al. Stickler syndrome without eye involvement is caused by mutations in COL11A2, the gene encoding the alpha2(XI) chain of type XI collagen. J Pediatr 1998; 132:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/117\">",
"      Marcos JC, De Benyacar MA, Garc&iacute;a-Morteo O, et al. Idiopathic familial chondrocalcinosis due to apatite crystal deposition. Am J Med 1981; 71:557.",
"     </a>",
"    </li>",
"    <li>",
"     Ryan LM, McCarty DJ. Calcium pyrophosphate crystal deposition disease: Pseudogout; articular chondrocalcinosis. In: Arthritis and Allied Conditions, 12th Edition, McCarty DJ, Koopman WJ (Eds), Lea and Febiger, Philadelphia 1993. p.1835.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/119\">",
"      ZITNAN D, SITAJ S. [Chondrocalcinosis polyarticularis (familiaris): roentgenological and clinical analysis]. Cesk Rentgenol 1960; 14:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/120\">",
"      Baldwin CT, Farrer LA, Adair R, et al. Linkage of early-onset osteoarthritis and chondrocalcinosis to human chromosome 8q. Am J Hum Genet 1995; 56:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/121\">",
"      Hughes AE, McGibbon D, Woodward E, et al. Localisation of a gene for chondrocalcinosis to chromosome 5p. Hum Mol Genet 1995; 4:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/122\">",
"      Reginato AJ, Passano GM, Neumann G, et al. Familial spondyloepiphyseal dysplasia tarda, brachydactyly, and precocious osteoarthritis associated with an arginine 75--&gt;cysteine mutation in the procollagen type II gene in a kindred of Chiloe Islanders. I. Clinical, radiographic, and pathologic findings. Arthritis Rheum 1994; 37:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/123\">",
"      ZITNAN D, SIT'AJ S. Chondrocalcinosis articularis Section L Clinical and radiological study. Ann Rheum Dis 1963; 22:142.",
"     </a>",
"    </li>",
"    <li>",
"     Jiminez SA, Williams CJ, Karasick D, et al. Hereditary osteoarthritis. In: Osteoarthritis, Brandt KD, et al (Eds), Oxford University Press, Oxford 1998. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/125\">",
"      Matteucci BM. Metabolic and endocrine disease and arthritis. Curr Opin Rheumatol 1995; 7:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/126\">",
"      Bagge E, Ed&eacute;n S, Ros&eacute;n T, Bengtsson BA. The prevalence of radiographic osteoarthritis is low in elderly patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993; 129:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/127\">",
"      Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971; 53:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/128\">",
"      Schumacher HR Jr. Synovial inflammation, crystals, and osteoarthritis. J Rheumatol Suppl 1995; 43:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/129\">",
"      Neogi T, Nevitt M, Niu J, et al. Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum 2006; 54:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/130\">",
"      McCarthy GM. Calcium crystals and cartilage damage. Curr Opin Rheumatol 1996; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/131\">",
"      Doyle DV. Tissue calcification and inflammation in osteoarthritis. J Pathol 1982; 136:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/132\">",
"      Ali SY, Griffiths S. Formation of calcium phosphate crystals in normal and osteoarthritic cartilage. Ann Rheum Dis 1983; 42 Suppl 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/133\">",
"      Boivin G, Lagier R. An ultrastructural study of articular chondrocalcinosis in cases of knee osteoarthritis. Virchows Arch A Pathol Anat Histopathol 1983; 400:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/134\">",
"      Dieppe PA, Crocker PR, Corke CF, et al. Synovial fluid crystals. Q J Med 1979; 48:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/135\">",
"      Gibilisco PA, Schumacher HR Jr, Hollander JL, Soper KA. Synovial fluid crystals in osteoarthritis. Arthritis Rheum 1985; 28:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/43/29370/abstract/136\">",
"      Kalunian KC, Moreland LW, Klashman DJ, et al. Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial. Osteoarthritis Cartilage 2000; 8:412.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5499 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-393BA8AD0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29370=[""].join("\n");
var outline_f28_43_29370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4497799\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS AND POSSIBLE CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FEMALE SEX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OBESITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Risk reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Associated disability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LACK OF OSTEOPOROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Estrogen replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OCCUPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SPORTS ACTIVITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVIOUS INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Knee injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Amputation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MUSCLE WEAKNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MUSCLE STRENGTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY OF RISK ASSOCIATED WITH PHYSICAL EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROPRIOCEPTIVE DEFICITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Twin and non-twin sibling studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Genome-wide scanning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Hand OA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Knee OA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Haplotype associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Mutations in proteins involved in bone or articular cartilage structure or metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - COL2A1 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Other extracellular matrix proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Endocrine/metabolic genetic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Stickler syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Familial chondrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ACROMEGALY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      CALCIUM CRYSTALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4497799\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27113?source=related_link\">",
"      Clinical features and diagnosis of developmental dysplasia of the hip",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=related_link\">",
"      Diabetic neuropathic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=related_link\">",
"      Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19114?source=related_link\">",
"      Pathogenesis of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_43_29371="CAD as first CV event";
var content_f28_43_29371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentage of first atherosclerotic cardiovascular events as coronary heart disease in subjects in the Framingham study",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Number of CV events, all types",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Percent as coronary heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"       <td class=\"subtitle2\">",
"        Men",
"       </td>",
"       <td class=\"subtitle2\">",
"        Women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35 to 54",
"       </td>",
"       <td>",
"        352",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        33.0",
"       </td>",
"       <td>",
"        28.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55 to 64",
"       </td>",
"       <td>",
"        437",
"       </td>",
"       <td>",
"        329",
"       </td>",
"       <td>",
"        56.5",
"       </td>",
"       <td>",
"        52.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65 to 74",
"       </td>",
"       <td>",
"        358",
"       </td>",
"       <td>",
"        364",
"       </td>",
"       <td>",
"        65.4",
"       </td>",
"       <td>",
"        58.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75 to 94",
"       </td>",
"       <td>",
"        199",
"       </td>",
"       <td>",
"        312",
"       </td>",
"       <td>",
"        57.3",
"       </td>",
"       <td>",
"        48.1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     44-year follow-up of cohort and 20-year follow-up of offspring.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29371=[""].join("\n");
var outline_f28_43_29371=null;
var title_f28_43_29372="Tissue factor generate thrombin";
var content_f28_43_29372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80402&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tissue factor generates thrombin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 183px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29372=[""].join("\n");
var outline_f28_43_29372=null;
var title_f28_43_29373="Relationship between GFR and PTH";
var content_f28_43_29373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship between GFR and PTH with and without dietary phosphate restriction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between the glomerular filtration rate (GFR) and the plasma parathyroid hormone (PTH) concentration in two groups of dogs which developed renal failure: one maintained on a regular diet (solid line); and one treated with dietary phosphate restriction (dashed line). A decline in GFR led to a progressive rise in PTH levels with the regular diet; limiting phosphate intake prevented both phosphate retention and the development of secondary hyperparathyroidism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Slatopolsky, E, Caglar, S, Pennell, JP, et al, J Clin Invest 1971; 50:492.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29373=[""].join("\n");
var outline_f28_43_29373=null;
var title_f28_43_29374="Malignancy pulmonary nodule";
var content_f28_43_29374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Likelihood ratios for malignancy in solitary pulmonary nodules",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Characteristic",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Characteristic",
"probability",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Likelihood ratio for",
"malignancy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Malignant nodules",
"       </td>",
"       <td class=\"subtitle2\">",
"        Benign nodules",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0-1 cm",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        1,063",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1.1-2.0 cm",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        0.74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.1-3.0 cm",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        3.67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;3.0 cm",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        5.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Edge (chest radiography)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ill defined",
"       </td>",
"       <td>",
"        0.71",
"       </td>",
"       <td>",
"        0.28",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        152",
"       </td>",
"       <td>",
"        2.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Well defined, lobular",
"       </td>",
"       <td>",
"        0.89",
"       </td>",
"       <td>",
"        0.70",
"       </td>",
"       <td>",
"        1.27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Well defined, smooth",
"       </td>",
"       <td>",
"        0.11",
"       </td>",
"       <td>",
"        0.30",
"       </td>",
"       <td>",
"        0.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Tomographic appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malignant",
"       </td>",
"       <td>",
"        0.44",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        238",
"       </td>",
"       <td>",
"        37.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Indeterminate",
"       </td>",
"       <td>",
"        0.56",
"       </td>",
"       <td>",
"        0.76",
"       </td>",
"       <td>",
"        0.73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benign",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.23",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Edge (CT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Smooth",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        903",
"       </td>",
"       <td>",
"        0.30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lobulated",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        0.74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Irregular/spicular",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        5.54",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Calcification at tomography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcified",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        323",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noncalcified",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"       <td>",
"        0.66",
"       </td>",
"       <td>",
"        1.50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Calcification at CT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        in phantom (benign)",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        1,041",
"       </td>",
"       <td>",
"        0.01&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        in phantom",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        2.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Growth rate&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;7 d",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        217",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7-465 d",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        0.29",
"       </td>",
"       <td>",
"        3.40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &gt;465 d",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        0.46",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper/middle lobe",
"       </td>",
"       <td>",
"        0.74",
"       </td>",
"       <td>",
"        0.61",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        179",
"       </td>",
"       <td>",
"        1.22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower lobe",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"       <td>",
"        0.39",
"       </td>",
"       <td>",
"        0.66",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Maximal cavity wall thickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &le;4 mm",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.47",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        123",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5-15 mm",
"       </td>",
"       <td>",
"        0.37",
"       </td>",
"       <td>",
"        0.52",
"       </td>",
"       <td>",
"        0.72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;16 mm",
"       </td>",
"       <td>",
"        0.59",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        37.97",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        20-29 y",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        529",
"       </td>",
"       <td>",
"        0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        30-39 y",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        40-49 y",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        0.94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        50-59 y",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        1.90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        60-69 y",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        2.64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;70 y",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        -&bull;",
"       </td>",
"       <td>",
"        4.16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\" rowspan=\"1\">",
"        Smoking history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Never smoked",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.33",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        9,036",
"       </td>",
"       <td>",
"        0.19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Current cigarette smoker",
"       </td>",
"       <td>",
"        0.58",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"       <td>",
"        2.27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pipe/cigar smoker",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        1.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ex-cigarette smoker",
"       </td>",
"       <td>",
"        0.24",
"       </td>",
"       <td>",
"        0.26",
"       </td>",
"       <td>",
"        0.92",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ex-pipe/cigar smoker",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"       <td>",
"        0.08",
"       </td>",
"       <td>",
"        0.55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Hemoptysis",
"       </td>",
"       <td>",
"        0.09",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        215",
"       </td>",
"       <td>",
"        5.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Previous malignancy",
"       </td>",
"       <td>",
"        0.15",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        845",
"       </td>",
"       <td>",
"        4.95",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The denominator of the likelihood ratio is omitted from the table for simplicity (eg, 0.52:1).",
"     <br>",
"      &bull; A weighted likelihood ratio was estimated by combining results of studies.",
"      <br>",
"       &Delta; The standardization of the reference nodule has changed; 0.07 may be a better estimate for the likelihood ratio.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Gurney, JW, Radiology 1993; 186:405.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29374=[""].join("\n");
var outline_f28_43_29374=null;
var title_f28_43_29375="HIT mechanism";
var content_f28_43_29375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Mechanism of heparin induced thrombocytopenia (HIT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 474px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mechanism of heparin induced thrombocytopenia (HIT). Some individuals&nbsp;produce IgG antibodies directed against heparin complexed with platelet factor 4 (PF4). Platelet Fc receptors&nbsp;bind the antibody-heparin-PF4 immune complex. This leads to platelet activation and microparticle release, which contribute to thrombosis. Thrombocytopenia occurs by two mechanisms: removal of platelets with bound IgG by splenic macrophages, and platelet consumption caused by thrombus formation. PF4 can also bind heparan sulfate on vascular endothelial cells; subsequent binding of the pathologic antibody to this PF4-heparan sulfate complex can&nbsp;injure the endothelium, which further promotes thrombosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laura Ibsen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_43_29375=[""].join("\n");
var outline_f28_43_29375=null;
